PosterSessionOnline

EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

The International Liver Congress 2017

19-23 April 2017 Amsterdam

N. Poster

Poster title

Applicant name

Status


THU-001	Risk factors of early emergent hospital readmission and 6-month mortality in patients with cirrhosis after a recovery from bacterial or fungal infection	Filippo Morando	Received

SAT-001	Human umbilical cord mesenchymal stem cell treatment improves survival rate in patients with decompensated liver cirrhosis	Ming Shi	Received

SAT-002	Cirrhosis and acute on chronic liver failure: is ammonia a predictor of hepatic encephalopathy and mortality?	Mohammed Sheikh	Received

THU-002	Pregnancy in women with idiopathic non-cirrhotic portal hypertension: results of a multicentric European study on maternal and fetal management and outcome	Filipe Teixeira Andrade	Received

FRI-002	Macrophage activation markers sCD163 and mannose receptor predict survival and correlate with markers of gut permeability in patients with liver cirrhosis	Florian Rainer	Received

FRI-003	Non malignant portal vein thrombosis in cirrhotic patients: is the anticoagulation safe and efficient?	Gargouri Dalila	Received

THU-003	Von Willebrand Factor as a predictor of short-term morbidity and mortality in comparison with conventional scoring systems	Aditya Vivekanand Kulkarni	Received

THU-004	Early initiation of carvedilol is safe and cost effective in cirrhotic patients presenting with upper GI bleed following endoscopic therapy: results of a prospective randomized trial	Adnan Salim	Received

SAT-004	Prolonged intensive care support of patients with acute on chronic liver failure and CLIF-C ACLF score greater than 70 may be futile	Nekisa Zakeri	Received

SAT-005	Transjugular intrahepatic portosystemic shunt before planned abdominal surgery in cirrhotic patients	Nicolas Tabchouri	Received

THU-005	Platelet count, spleen length and platelet count/spleen length ratio for the diagnosis of oesophageal varices in patients with hepatic cirrhosis. A systematic review and meta-analysis	Agostino Colli	Received

FRI-006	Validation of the Baveno VI criteria for the screening of gastroesophageal varices in our hospital	Gema Molina Arriero	Received

THU-006	Rapid change of liver stiffness after variceal ligation and TIPS implantation	Felix Piecha	Received

SAT-006	Farnesoid-X Receptor single nucleotide polymorphism rs35724 is potentially associated with patients` outcome in decompensated liver cirrhosis	Cornelius Engelmann	Received

SAT-007	The long-term impact of sustained virologic response (SVR) on patient-reported outcomes (PROS) in cirrhotics with Hepatitis C (HCV) infection	Zobair M Younossi	Received

FRI-007	Abnormal MOCA scores are common and predict morbidity and mortality in patients with cirrhosis	Michael Ney	Received

THU-007	A chronic disease management model for chronic liver failure is cost-effective; cost-effectiveness analysis	Alan J Wigg	Received

THU-008	Spontaneous bacterial empyem revisited	Alberto Amador	Received

FRI-008	Porto- systemic shunt embolization and recurrent ascites: a single centre case series	Graziella Privitera	Received

SAT-008	Rifaximin for the prevention and treatment of hepatic encephalopathy: a systematic review with meta-analyses of randomised controlled trials	Nina Kimer	Received

FRI-009	Early recurrent overt hepatic encephalopathy is associated with poor survival in patients with cirrhosis after transjugular intrahepatic portosystemic shunt	Guohong Han	Received

THU-009	Outcome of liver transplant recipients after the first episode of bacterial infection	Alberto Ferrarese	Received

SAT-009	New classification of gastric varices: a twenty-year experience	Nipun Verma	Received

THU-010	Decreased hypercoagulable state in hepatitis C virus-cirrhotic patients treated with DAA: the outcome revolution	Alberto Zanetto	Received

FRI-010	Hepatic encephalopathy in cirrhotic patients with bacterial infections: prevalence, clinical characteristics and correlation with prognosis: a prospective study	Gustavo Henrique Santos Pereira	Received

FRI-011	Serum creatinine level is not appropriate in predicting prognosis in patients with liver cirrhosis and sarcopenia	Han Ah Lee	Received

THU-011	Long-term survival after hospital discharge in cirrhotic patients previously hospitalized in intensive care unit for an acute event: a 6 year cohort study	Fabien Marquion	Received

SAT-011	Terlipressin is superior to Noradrenaline in the management of acute kidney injury (AKI) in patients with ACLF	Vinod Arora	Received

SAT-012	Non-invasive tools to ruling out large varices: RESIST-HCV vs. Baveno VI criteria in a large cohort of patients with HCV cirrhosis	Vincenza Calvaruso	Received

THU-012	Usefulness of the six-minute walk as a predictor of mortality in patients with decompensated cirrhosis	Ernesto Marquez Guillen	Received

FRI-012	time in HE in cirrhotic patients with an acute episode (=grade 2) determines short and long-term survival	Meritxell Ventura Cots	Received

FRI-013	Palliative care access for hospitalized patients with end stage liver disease across the United States	Mayur Brahmania	Received

THU-013	High serum human beta-defensin-1 is associated with increased short-term mortality in patients with decompensated cirrhosis	Alexandra Alexopoulou	Received

THU-014	Prospective study of gastrointestinal tract colonization with multidrug resistant bacteria and potential association with infection development and survival in patients with decompensated cirrhosis	Alexandra Alexopoulou	Received

FRI-014	Cirrhotic patients in ICU with gastro-intestinal bleeding managed according to recent guidelines display altered brain hemoglobin oxygen´s saturation assessed by near infrared spectroscopy	Maxime Mallet	Received

SAT-014	Decrease in cardiac work in patients with alcoholic hepatitis: role of inflammation?	Olivier Roux	Received

FRI-015	Von Willebrand factor antigen predicts portal hypertensive bleeding, infections, and survival, independently of portal hypertension severity	Mattias Mandorfer	Received

THU-015	Single center validation of scores for prediction of mortality in patients with acute-on-chronic liver failure or acute decompensation of cirrhosis without acute-on-chronic liver failure	Alexandra Alexopoulou	Received

SAT-015	PALBI - the platelet-albumin-bilirubin score – a better predictor of outcome of acute variceal bleeding	Omar Elshaarawy	Received

THU-016	Uncontrolled glycaemia increases the risk of developing spontaneous bacterial peritonitis in patients with cirrhosis	Fatima Higuera-de La Tijera	Received

FRI-016	Performance of FibroScan to detect large esophageal varices in chronic liver diseases is improved by a novel spleen-dedicated examination	Horia Stefanescu	Received

SAT-016	Prevalence and clinical impact of rectal colonization by multidrug-resistant bacteria in critically ill patients with and without cirrhosis	Veronica Enith Prado Gonzalez	Received

SAT-017	Real world impact of rifaximin-a use in hepatic encephalopathy patients with advanced liver disease or continued alcohol misuse: a post-hoc analysis of the IMPRESS study	Paola Di Maggio	Received

THU-017	Metabolic risk factors increase the risk of hepatocellular carcinoma in patients with hepatitis C cirrhosis	Alina Kutsenko	Received

FRI-018	Presepsin (soluble CD14 subtype) levels in cirrhotic patients with bacterial infections and/or portal hypertension related bleeding presented with or without acute kidney injury	Ioannis S Elefsiniotis	Received

SAT-018	The addition of splenic and superior mesenteric vein respiratory excursions to Baveno VI criteria can save more endoscopies without compromising its diagnostic accuracy	Paolo Del Poggio	Received

THU-018	GAVE is more common in patients with NASH-cirrhosis	Aline LeCleac´h	Received

SAT-019	Screening of large esophageal varices by a simple algorithm of blood markers	Paul Cales	Received

THU-019	Mortality of variceal bleeding admitted to the intensive care unit: an Australasian study	Ammar Majeed	Received

FRI-019	Adipocyte fatty acid binding protein in cirrhosis: increased hepatic gene expression and plasma levels and correlation with clinical outcomes	Isabel Graupera	Received

FRI-020	A multimodality assessment of liver fibrosis in asymptomatic Fontan patients	Isabelle Munsterman	Received

SAT-020	Fat mass and visceral fat inversely correlate with disease severity in patients with liver cirrhosis - a Bioelectrical impedance analysis based study	Varsha Shasthry	Received

THU-020	C reactive protein contributes to the early prediction of 90-day mortality risk in acutely decompensated cirrhotic patients	Ana Clemente	Received

THU-021	Hepatic and non-hepatic events after obtaining a SVR in patients with genotype 1b liver cirrhosis-short time follow-up-single center experience	Ana Maria Singeap	Received

FRI-021	Short-term metabolic alterations following liver transplantation	Iva Košuta	Received

THU-022	The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy	Andrei Mihai Voiosu	Received

FRI-022	NACSELD acute-on-chronic liver failure (NACSELD-ACLF) predicts 30-day mortality in admitted cirrhotic patients	Jacqueline G Oleary	Received

SAT-022	DASIMAR - a novel prognostic biomarker for acute cirrhosis decompensation to guide early intervention - a prospective multicenter study	Peter Holland-Fischer	Received

SAT-023	For diagnosis of acute kidney injury in decompensated cirrhosis the estimation of baseline serum creatinine using Modification of Diet in Renal Disease formula is not accurate enough	Petra Fischer	Received

THU-023	Adverse events and the development of acute on chronic liver failure in patients with cirrhosis undergoing endoscopic retrograde cholangiopancreatography: A retrospective, multicenter, case-control study	Andres Cardenas	Received

FRI-023	When to refer end-stage liver disease patients to palliative care: a survey of practicing liver and palliative care clinicians	James Philip Esteban	Received

FRI-024	An Innovative app focused on patients and caregivers significantly decreases avoidable and HE-related readmissions in cirrhotic patients	Jasmohan Singh Bajaj	Received

THU-024	Intestinal colonisation by Veillonella spp. is predictive for mortality in stable cirrhosis and could be partially reduced by a multispecies probiotic in a randomized placebo controlled trial	Angela Horvath	Received

SAT-024	The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease	Philip Georg Ferstl	Received

THU-025	Prevalence of portal trombosis related to the degree of portal hypertension	Joaquin Cabezas Gonzalez	Received

FRI-025	Albumin use and acute kidney injury in a large real-world analysis of cirrhotic inpatients	Jasmohan S Singh Bajaj	Received

THU-026	The natural history of covert hepatic encephalopathy in cirrhotic patients in a tertiary care hospital	Anjiang Wang	Received

FRI-026	Oral glutamine challenge predicts risk and defines hepatic encephalopathy types	Javier Ampuero	Received

SAT-026	Hepatocyte microvesicle levels predict 6-month survival in patients with cirrhosis: results of a prospective study on 242 patients	Pierre-Emmanuel Rautou	Received

FRI-027	Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis	Javier Fernandez	Received

THU-027	Long-term prognosis following acute-on-chronic liver failure	Eileen L. Yoon	Received

SAT-027	Modification of deranged systemic hemodynamic parameters and impaired intestinal permeability with slow infusion of furosemide and albumin with or without terlipressin in patients with refractory ascites	Prabhat Narain Sharma	Received

THU-028	Clinical significance of urinary neutrophil gelatinase-associated lipocalin measurement in differentiating various etiologies of acute kidney injury in cirrhotic patients	Eileen L. Yoon	Received

FRI-028	The Quick SOFA, a simple bedside score, identifies hospitalized cirrhotic patients with poor outcomes	Jean-Paul Cervoni	Received

SAT-028	Impact of antiviral treatment in patients with HCV cirrhosis: a reduction in hospital admission rates	Prashant Bamania	Received

SAT-029	Occult advanced fibrosis in the general population	Rifaat Safadi	Received

THU-029	Bacterial deoxyribonucleic is frequent in blood samples of patients with compensated cirrhosis and obesity and is associated with lack of decrease of portal pressure after an intensive lifestyle intervention	Annalisa Berzigotti	Received

SAT-030	Carvedilol is associated with improved survival in patients with decompensated cirrhosis	Rohit Sinha	Received

THU-030	L-ornithine L-aspartate for hepatic encephalopathy: a systematic review with meta-analyses of randomised controlled trials	Ee Teng Goh	Received

THU-031	Nutritional habits in patients with chronic liver disease: adherence of real life diet to international guidelines and its association with disease stage	Edoardo Poli	Received

SAT-031	Frequency and causes of malnutrition in liver disease patients: results from a multi-centric cross-sectional survey from gastroenterology tertiary clinics	Roxana Vadan	Received

FRI-031	Performance of upper gastrointestinal bleeding risk assessment scores in variceal bleeding: a prospective international multicenter study	Yung Ka Chin	Received

THU-032	Resistant bacterial infections in cirrhosis: a French observational prospective multicentre nationwide study (RESIST study)	Arnaud Pauwels	Received

SAT-033	Assessment of Sepsis-3 criteria in patients with cirrhosis and bacterial infections	Salvatore Piano	Received

FRI-033	Acute hemodynamic response to beta-blockers: factors influencing its outcome	Antonio Cuadrado Lavin	Received

FRI-034	Patients with alcoholic-related cirrhosis have high burden of coronary arteriosclerosis compared to non-alcohol-related cirrhosis	Karen Vagner Danielsen	Received

SAT-034	Impact of acute-on-chronic liver failure on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome	Salvatore Piano	Received

THU-034	Systematic review with meta-analysis: liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding	Astrid Marot	Received

THU-035	A new classification of chronic portal vein occlusion for assessing the feasibility of recanalization in non-cirrhotic patients	Astrid Marot	Received

SAT-035	Prediction in-hospital mortality of acute esophagogastric variceal bleeding: which is the best score?	Sara Monteiro	Received

THU-036	Bioelectrical impedance vector analysis is an objective method for nutritional assessment in patients with cirrhosis	Astrid Ruiz-Margáin	Received

FRI-036	Medication beliefs predict low medication adherence in people with decompensated cirrhosis	Kelly Lee Hayward	Received

FRI-037	The association between serum sodium and rate of hepatic encephalopathy in cirrhosis patients with ascites	Lars Bossen	Received

THU-037	Comparison of heterozygous alpha-1 antitrypsin deficiency in unselected patients with liver cirrhosis and transplant recipients with the general population and liver donors	Benedikt Schaefer	Received

THU-038	The effect of planned care on resource use and end of life outcomes in patients with diuretic resistant ascites: a retrospective cohort study of deaths in England	Benjamin Hudson	Received

FRI-038	Presence of ACLF is the best predictor of mortality in patients with decompensated chronic liver disease managed in a non-specialist environment	Laura Burke	Received

FRI-039	Maternal and pregnancy outcomes in women with cirrhosis: Room for optimizing care	Mary Rinella	Received

THU-039	Human ascites microfibril-associated protein 4 is an independent predictor of mortality in decompensated cirrhosis	Bjørn Stæhr Madsen	Received

SAT-039	HCV cirrhosis: liver volume as a non-invasive predictor of liver recovery post DAA treatment	Tommaso Di Maira	Received

SAT-040	Malnutrition is an independent predictor of immune dysfunction in cirrhotic patients	Siddharth Sood	Received

THU-040	New International club of ascites definition of acute kidney injury applied at admission is not independently associated with mortality in patients with acute-on-chronic liver failure	C Ganesh Pai	Received

FRI-040	Prospective study to evaluate the resolution of minimal hepatic encephalopathy after antiviral treatment in patients with HCV liver cirrhosis	Marta Hernandez Conde	Received

FRI-041	Rifaximin-a is associated with reductions in emergency department resource use in UK patients with hepatic encephalopathy: real world evidence from the IMPRESS study	Mark Hudson	Received

THU-041	Hepatic hydrothorax in patients with cirrhosis and ascites – its prevalence and association with other cirrhosis complications	Daniela Matei	Received

SAT-041	Albumin-bilirubin grade allows accurate prediction of live births in patients with liver disease	Tiong Yeng Lim	Received

SAT-042	Alcoholic cirrhosis is not a risk factor for acute myocardial infarction: a nationwide cohort study	Thomas Deleuran	Received

THU-042	Proton pump inhibitors increase the risk for hepatic encephalopathy in patients with cirrhosis and ascites	Daniela Matei	Received

FRI-042	A standardized CT estimation of liver volume is associated to the severity of cirrhosis and predicts the risk of decompensation	Ana Clemente	Received

FRI-043	Cellulitis is a common precipitant of acute kidney injury and mortality in patients with cirrhosis	Luis Téllez	Received

THU-043	Ethnic differences in overall survival of patients with cirrhosis: results of a cohort of 2939 United States patients with long-term follow-up	Pauline Nguyen	Received

SAT-043	Sarcopenia represents a risk factor for the development of hepatic encephalopathy after transjugular intrahepatic portosysthemic shunt	Silvia Nardelli	Received

SAT-044	Effect of spontaneous bacterial peritonitis on mortality among patients with alcoholic cirrhosis and ascites	Thomas Deleuran	Received

THU-044	Evaluation of the CLIF-C ACLF score in critically ill cirrhotic patients in intensive care units in Europe and North America: a multicenter cohort study	Constantine Jason Karvellas	Received

FRI-044	Portosystemic shunts in cirrhosis are associated to more complications and deteriorated quality of life: an international cohort study	Macarena Simón-Talero	Received

FRI-045	Non-invasive measures to predict the presence of oesophageal varices in real life practice	Mafalda Sousa	Received

THU-045	Urinary MicroARNs as potential biomarkers to predict the evolution of kidney function after liver transplantation in patients with cirrhosis	Clement Lejealle	Received

SAT-045	The optimal dose of concomitant albumin for the treatment of hepatorenal syndrome type 1 - what is it?	Stephen Chris Pappas	Received

SAT-046	Bacterial infections in cirrhosis – a retrospective analysis updating on microbiology and resistance rates	Theresa Bucsics	Received

THU-046	The impact of esophageal varices on the prognosis of patients with hepatocellular carcinoma after surgical resection: A propensity score matching analysis	Chung-Yu Chang	Received

FRI-046	GR3027 reverses neurosteroid-induced, GABAA receptor-mediated inhibition of brain function: A human challenge study	Maja Johansson	Received

FRI-047	Changes in the model for end-stage liver disease (MELD) scores on day 7 predict mortality in acute on chronic liver disease: the delta-MELD project	Majd B Protty	Received

SAT-047	Efficacy of nutritional therapy on quality of life in liver cirrhosis with minimal hepatic encephalopathy- randomized controlled trial	Sudhir Maharshi	Received

THU-047	Not all of the patients with hepatitis B-related hepatocellular carcinoma require endoscopic screening for esophageal varices: a large cohort study	Chung-Yu Chang	Received

THU-048	End-stage cirrhotic patients rarely receive adequate palliative care. Can we do something earlier?	Chun-Han Cheng	Received

SAT-048	The National Early Warning Score accurately discriminates the risk of serious in-hospital adverse outcomes in patients with liver disease	Therasa J. Hydes	Received

FRI-048	Effect of terlipressin treatment in liver transplant-eligible patients with hepatorenal syndrome	Marc Nguyen-Tat	Received

FRI-049	Prevalence and clinical implications of hemophagocytic syndrome in patients with infection-induced acute on chronic liver failure – a retrospective pilot study	Mariana Verdelho Machado	Received

THU-049	External validation of a new equation predicting glomerular filtration rate in patients with cirrhosis candidates for liver transplantation and impaired renal function	Claire Francoz	Received

SAT-049	Proton pump inhibitors are associated with a higher risk for spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites	Tammo Lambert Tergast	Received

SAT-050	Predictors of nosocomial spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis and ascites	Tammo Lambert Tergast	Received

FRI-050	The emerging role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses	Marcus Maximilian Mücke	Received

FRI-051	Abnormalities in skin temperature and its 24-hour rhythm in patients with cirrhosis: sleep-wake and general clinical implications	Maria Garrido	Received

SAT-051	Erythropoietin treatment reduces inflammatory reaction and improves liver regeneration after major hepatic resection in cirrhotic rat models	Sukwon Suh	Received

SAT-053	The alternate renin angiotensin system is upregulated and Ang-(1-7) mediates vasodilatation in human cirrhosis	Stephen Casey	Received

FRI-053	Glutamine synthetase in endothelial cells of the blood-brain barrier: less but not insignificant?	Mariana M Oliveira	Received

FRI-054	Plasma lipid mediator (LM) profiling identifies hyper- and hypo-activated groups of patients with ACLF and targeted 20% human albumin solution infusion recalibrates abnormalities	Louise China	Received

SAT-054	PTTG1/DLK1, a new signaling pathway involved in the pathogenesis of liver fibrosis	Silvia Carvajal	Received

THU-054	TGR5 plays a protective role against portal hypertension in LCA induced liver damage in mice	Caroline Klindt	Received

SAT-055	Decreased levels of crucial complement pathway components in patients with advanced liver cirrhosis	Signe Glargaard	Received

FRI-055	Albumin binding capacity is impaired in decompensated liver cirrhosis and dysfunction is reversed by targeted in vivo 20% human albumin solution infusions	Louise China	Received

THU-055	Minimal hepatic encephalopathy is associated with increased capacity to eliminate superoxide and peroxynitrite in lymphocytes	Carmina Montoliu	Received

FRI-056	Survival predictors in cirrhotic patients with refractory ascites treated with transjugular intrahepatic portosystemic shunt	Marta Aicart-Ramos	Received

SAT-056	Collapsed reticular network during the initiation and progression of hepatic fibrosis in rat and human livers	Shi-Lei Wen	Received

THU-056	Extracellular matrix turnover is regulated in 3D disease-specific human liver scaffolds engineered with human hepatic stellate cells	Diana Julie Leeming	Received

THU-057	Low sensitivity to thrombomodulin in patients with cirrhosis; Impact of factor VIII increase and protein C deficiency	Armand Abergel	Received

SAT-057	Toll-like receptor polymorphisms compromise the inflammatory response against translocated bacterial antigens in cirrhosis	Paula Piñero Romero	Received

FRI-057	Intestinal inflammation worsens epithelial barrier function in rats with cirrhosis and ascites: role of commensal gut flora	Agustín Albillos	Received

FRI-058	Cannabinoid receptor 1 mediates M1 polarization of bone marrow-derived monocytes/macrophages via RhoA/NF-?B p65 and ERK1/2 signaling pathways respectively in mouse fibrotic liver	Le Yang	Received

SAT-058	Thyroid Hormone receptor regulates hepatic stellate cell activation	Paul P. Manka	Received

THU-058	Genetic determinants influencing on overt hepatic encephalopathy and acute-on-chronic liver failure	Antonio Gil-Gómez	Received

THU-059	Impaired cerebral oxygenation, but preserved cerebrovascular reactivity, in an animal model of hepatic encephalopathy	Anna Hadjihambi	Received

SAT-059	B. pseudocatenulatum CECT7765 effect on intestinal microbiota of rats with bile duct ligation	Oriol Juanola Juárez	Received

FRI-059	Beneficial effects of octrotide on intrahepatic angiogenesis via somatostatin receptor 2 in portal hypertensive and cirrhotic rats	Jinhang Gao	Received

SAT-060	Treatment with anti-TNFa reduces neuroinflammation and restores neurotransmission, learning and motor coordination in rats with hepatic encephalopathy	Vicente Felipo	Received

THU-060	Brain glymphatic clearance is impaired in a rat model of cirrhosis	Anna Hadjihambi	Received

THU-061	Progression of cirrhotic liver disease towards acute-on-chronic liver failure triggers changes in innate immune cell phenotype and their response to pro-inflammatory stimuli	Alexander AN Maini	Received

SAT-062	New animal model of obesity and chronic liver disease to provide insights on non-alcoholic liver disease-induced hepatic encephalopathy	Ochoa-Sanchez Rafael	Received

FRI-062	Functional cortical connectivity is disturbed in patients with cirrhosis even when neuropsychometric performance is unimpaired	Harry D Zacharias	Received

THU-062	Extracellular vesicles induce renal tubular cells apoptosis, oxidative stress and functional abnormalities in patients with an acute decompensation of cirrhosis	Alessandra Brocca	Received

FRI-063	Inhibition of macrophage infiltrations by thalidomide improves muscle wasting of cirrhotic rats	Han-Chieh Lin	Received

SAT-063	Impact of von Willebrand factor/ADAMTS-13 on the pro-coagulant imbalance detected in cirrhosis	Vincenzo La Mura	Received

THU-063	A novel population of immunosuppressive CD8 T cells is expanded in patients with decompensated liver disease	Fanny Lebosse	Received

THU-064	Simvastatin neither reduces gut bacterial translocation nor sistemic/mesenteric inflammation in cirrhotic rats with ascites	Agustín Albillos	Received

SAT-064	Effects of melatonin in hepatopulmonary syndrome induced biliar duct ligation in rats	Norma Possa Marroni	Received

SAT-065	Protective effect of melatonin on carbon tetrachloride-induced chronic hepatotoxicity	Norma Possa Marroni	Received

THU-065	Osteoprotegerin production and profibrotic activity in liver fibrosis are TGFß dependent	Adhyatmika Adhyatmika	Received

FRI-065	Activation of proinflammatory citokines is involved in muscle wasting in mice model of carbon tetrachloride induced liver cirrhosis	Michela Giusto	Received

FRI-066	Vascular morphology alterations during liver cirrhogenesis in rats	Geert Peeters	Received

THU-066	Osteoprotegerin is more than a serum marker in liver fibrosis	Adhyatmika Adhyatmika	Received

SAT-067	Regulation of the NLRP3 inflammasome in monocytes and macrophages from patients with decompensated cirrhosis by low-dose genotoxic stress	Nilay Koese	Received

FRI-067	Impact of sustained virological response to interferon therapy for chronic hepatitis C on recurrence and long-term survival in patients with hepatocellular carcinoma	Hiroji Shinkawa	Received

SAT-068	Elevated levels of circulating osteopontin in patients with cholangiocarcinoma predict poor survival after tumor resection	Sven H. Loosen	Received

THU-068	Trunk and branch drivers in hepatocellular carcinoma: impact of molecular heterogeneity	Agrin Moeini	Received

SAT-069	Pathomolecular scoring and diagnostic algorithm of atypical hepatocellular adenomas: a clue for malignant transformation	Valérie Paradis	Received

THU-069	The systemic inflammatory response is a prognostic marker in human immunodeficiency virus-infected patients with hepatocellular carcinoma	David James Pinato	Received

FRI-070	Development of de novo and recurrent hepatocellular carcinoma in a Romanian cohort of compensated HCV genotype 1b liver cirrhosis with SVR after 3D and ribavirin therapy	Liana Gheorghe	Received

SAT-070	Serum Wisteria Floribunda agglutinin-positive sialylated mucin 1 as a biomarker of hepatic progenitor cell/biliary features in hepatocellular carcinoma and of recurrence after curative therapy	Nobuharu Tamaki	Received

THU-070	Rising incidence of hepatocellular carcinoma in a Spanish health area between 2008 and 2016	Alberto Lue´	Received

THU-071	Laparoscopic ablation for hepatocellular carcinoma: proposal of a 6-months mortality score for patient selection based on more than 1000 procedures	Alessandro Vitale	Received

SAT-071	ASS1 immunohistochemistry identifies unclassified hepatocellular adenoma. Experience of a single French liver center	Paulette Bioulac-Sage	Received

FRI-071	Development of risk prediction model for hepatocellular carcinoma progression of indeterminate nodules in hepatitis B virus-related cirrhotic liver	Hyo Jung Cho	Received

SAT-072	Higher rates of cirrhosis, decompensation, and hepatocellular carcinoma (HCC) in Asian and Hispanic patients with Hepatitis C (HCV) Infection compared to White and Black ethnicity regardless of gender differences: a single center study in the U.S.	Pauline Nguyen	Received

THU-072	Pancreatic insufficiency related to hepatocellular carcinoma treatment: early detection and treatment improves therapeutic adherence	Alvaro Diaz-Gonzalez	Received

THU-073	Mipsagargin, a PSMA-directed prodrug, provides clinical benefit in patients with advanced sorafenib-refractory hepatocellular carcinoma	Devalingam Mahalingam	Received

SAT-073	The prognosis of single large hepatocellular carcinoma was distinct from the BCLC stage A or B	Pei-Chang Lee	Received

FRI-074	Determinants of long term survival and recurrence patterns after radiofrequency ablation for hepatocellular carcinoma developed on cirrhosis	Manon Allaire	Received

SAT-074	Validation of novel eligibility criteria by integrating ALBI grade and progression pattern for sorafenib-failed hepatocellular carcinoma	Pei-Chang Lee	Received

FRI-075	Conditional probability of long-term survival in patients with locally advanced and metastatic hilar cholangiocarcinoma	Marcia Gaspersz	Received

SAT-075	The long-term outcomes of patients with the Barcelona Clinic Liver Cancer stage 0 hepatocellular carcinoma after radiofrequency ablation therapy	Pei-Chang Lee	Received

THU-075	Albumin-Bilirubin grade based novel risk prediction model for patients with hepatocellular carcinoma undergoing chemoembolization	Dong Hyun Sinn	Received

THU-076	CEUS LI-RADS are effective in predicting the risk hepatocellular carcinoma of liver nodules	Fabio Piscaglia	Received

SAT-076	Polymorphisms in the cyclooxygenase-2 (COX-2) gene, vascular endothelial growth factor (VEGF) and methylenetetrahydrofolate reductase (MTHFR) gene in patients with hepatocellular carcinoma and hepatitis C virus infection	Sylene Coutinho Rampche de Carvalho	Received

FRI-076	The prognostic value of hepatic artery and portal vein involvement in patients with perihilar cholangiocarcinoma	Marcia Gaspersz	Received

FRI-077	Black hepatocellular carcinoma patients diagnosed after 2010 have worse long-term survival than white patients	Jacqueline Estevez	Received

SAT-077	Relationship between overall survival and time to progression after transarterial chemoembolization therapy in patients with hepatocellular carcinoma	Tadaaki Arizumi	Received

THU-077	Prospective validation of a score to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis that takes into account sustained virological response. Influence of direct-acting antivirals	Andres Castaño	Received

SAT-078	Prognostic impact of serum alpha-fetoprotein in patients with hepatocellular carcinoma: an international collaborative study	Philip Broadhurst	Received

FRI-078	Temporary suspension of sorafenib by adverse effects is associated with longer survival in patients with hepatocellular carcinoma	Maria Varela	Received

FRI-079	Functional health literacy can affect patient perception for the need for liver imaging for HCC screening	Jasmohan Singh Bajaj	Received

SAT-079	Serum biomarker (´GALAD´) response after resection of hepatocellular carcinoma: impact of tumour recurrence	Philip J Johnson	Received

THU-079	Advanced BCLC hepatocellular carcinoma includes a very heterogeneous patient population treatable with different therapies and with different prognosis	Francesca Garuti	Received

THU-080	Serum microRNAs as biomarkers for cirrhosis and hepatocellular carcinoma in Hepatitis C	Anna Weis	Received

SAT-080	Hepatocellular carcinoma recurrence after direct antiviral agent treatment: a european multicentric study	Philippe Kolly	Received

FRI-080	Telomerase activity: a valuable marker of hepatocelluar carcinoma development in cirrhotic hepatitis C patients	Nihal Mohamed El-Habachi	Received

FRI-081	Identification of actionable mutations in circulating cell-free tumour DNA as a prognostic biomarker in hepatocellular carcinoma	Jessica Howell	Received

THU-081	Interferon-free therapy of chronic hepatitis C does not change the short-term risk for de novo hepatocellular carcinomas in patients with liver cirrhosis	Friederike Mettke	Received

THU-082	Resection of larger hepatocellular adenomas: when is it justified?	Anne Julia Klompenhouwer	Received

FRI-082	The risk of hepatitis B virus reactivation is considerably high during sorafenib therapy in patients with advanced hepatocellular carcinoma	Ji Hye Seo	Received

SAT-082	The diagnostic and prognostic values of serum PIVKA-II in Thai patients with hepatitis B-related hepatocellular carcinoma	Pisit Tangkijvanich	Received

SAT-083	Adjuvant Huaier granule for hepatocellular carcinoma after curative resection: A phase IV, multicenter, randomized, and parallel-group controlled clinical trial	Qian Chen	Received

FRI-083	Prognostic significance of co-expression of programmed cell death 1 and its ligand 1 in resectable hepatocellular carcinoma	Jihyun An	Received

FRI-084	Combined Effect of Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and Programmed Cell Death 1 Ligand 1 (PD-L1) expression in tumor infiltrating lymphocytes on prognostic outcomes after resection of hepatocellular carcinoma	Jihyun An	Received

SAT-084	Hepatocellular carcinoma and metabolic risk factors in a main reference center in Italy	Ramy Ibrahim Kamal Jouness	Received

THU-084	Predictors for successful downstaging in patients with BCLC intermediate stage hepatocellular carcinoma	Annelotte Broekhoven	Received

FRI-085	Neuroligin4 over expression on natural killer cells cause their impairment in patients with cirrhosis and hepatocellular carcinoma	Johnny Amer	Received

THU-085	Risk of hepatocellular carcinoma development in patients with cirrhosis of viral etiology assessed by protein induced by vitamin k absence or antagonist II	Gian Paolo Caviglia	Received

SAT-085	Significantly lower rates of cirrhosis and worse long-term survival in cryptogenic hepatocellular carcinoma compared to viral etiologies: results of a multi-center international cohort	Tomi Jun	Received

THU-086	The role of spleen stiffness measurement as predictor of hepatocellular carcinoma recurrence after curative resection in cirrhotic patients	Giovanni Marasco	Received

SAT-086	The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without pegylated interferon: a Belgian experience	Rob Bielen	Received

FRI-086	Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma	Martha M Kirstein	Received

THU-087	Portal vein infiltration in patients with hepatocellular carcinoma: the impact of correct classification	Arndt Weinmann	Received

SAT-087	Significance of serum exosomal miR-122 and miR-21 as a predictive biomarker in hepatocellular carcinoma patients who underwent transarterial chemoembolization	Tomoyuki Suehiro	Received

SAT-088	Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma	Rocco Granata	Received

THU-088	Management of people with early or very early stage hepatocellular carcinoma: an attempted network meta-analysis	Avik Majumdar	Received

SAT-089	A combined bile and urine proteomic test for cholangiocarcinoma diagnosis in patients with biliary strictures of unknown origin	Torsten Voigtländer	Received

FRI-089	Safety and efficacy of chemosaturation in patients with primary and secondary liver tumours: a single-centre experience after 54 treatments	Martha M Kirstein	Received

THU-089	The effect of antiviral treatment on hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma	Gab Jin Cheon	Received

SAT-090	Extent of portal invasion in patients with hepatocellular carcinoma: the more, the worse?	Roman Kloeckner	Received

THU-090	Operability of perihilar cholangiocellular carcinoma can be reliably predicted by combination of endoscopic retrograde cholangiography, endoscopic ultrasound and computer tomography as variables in the European staging system	Bernhard Schlevogt	Received

FRI-090	Improved prediction of survival by a risk factor-integrated inflammatory score in Sorafenib treated hepatocellular carcinoma	Martin Franz Sprinzl	Received

SAT-091	Soluble Axl identifies patients at higher risk for hepatocellular carcinoma development: results from a large scale multicenter analysis	Wolfgang Mikulits	Received

FRI-091	Novel circulating cell free DNA methylation alterations as a biomarker for the detection of hepatocellular carcinoma	Ju Dong Yang	Received

THU-092	Alpha-fetoprotein levels before and after sustained virological response with direct- acting antivirals in patients with liver cirrhosis due to hepatitis C virus	Carmen Alvarez-Navascues	Received

FRI-092	Validation of the ALBI grade as a substitute for the Child-Pugh class in the BCLC classification of hepatocellular carcinoma and of the additional value provided by the Neutrophil-to-Lymphocyte Ratio	Matteo Colombo	Received

SAT-092	Circulating tumour-associated microparticles in liver cancer: a question of tumour diameter and volume?	Sabine Katharina Urban	Received

SAT-093	Characteristics of conversion to 2nd line treatment in sorafenib-treated advanced hepatocellular carcinoma patients	Sadahisa Ogasawara	Received

FRI-093	The optimal cutoff value of serum alpha-fetoprotein in the diagnosis of hepatocellular carcinoma	Jung-Fa Tsai	Received

FRI-094	External validation of the ITA.LI.CA prognostic system for patients with hepatocellular carcinoma: a multicenter cohort study	Mauro Borzio	Received

SAT-094	Impact of survival after moving onto the end-of-life care in patients with hepatocellular carcinoma	Sadahisa Ogasawara	Received

SAT-095	The expression of SALL4 and its clinical significance in hepatocellular carcinoma	Xiaoyu Wen	Received

THU-095	Clinical features of hepatocellular carcinoma in the elderly in a hepatitis B endemic country - a comparative study of 1430 cases	Chang-Chuen Mark Cheah	Received

FRI-095	Previous and resolved hepatitis B virus infection is not a risk factor for the development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus or alcohol	Carlos Rodríguez-Escaja	Received

SAT-096	Sorafenib therapy in orthotopic liver transplant recipients with hepatocellular carcinoma beyond Milan criteria on explant	Sanjaya Kumar Satapathy	Received

THU-096	Risk of hepatocellular carcinoma recurrence in hepatitis C cirrhotic patients treated with direct acting antivirals	Giuseppe Cabibbo	Received

FRI-096	Short-Course carbon-ion radiation therapy for hepatocellular carcinoma: a nationwide survey by Japan Carbon Ion Radiation Oncology Study Group (J-CROS 1504)	Kei Shibuya	Received

FRI-097	Treatment patterns and clinical outcomes for patients with hepatocellular carcinoma from China: a sub-analysis of the Global Hepatocellular Carcinoma BRIDGE Study	Minshan Chen	Received

SAT-097	Serial changes in serum biomarkers (GALAD model) prior to detection of HCC by ultrasound surveillance; application of statistical process control methodology	Sarah Berhane	Received

THU-097	Hepatocellular carcinoma and rheumatoid arthritis: a 10-year population-based propensity-score matched cohort study in Taiwan	Ching-Sheng Hsu	Received

SAT-098	Clinicopathological characteristics of Intrahepatic sarcomatoid cholangiocarcinoma: 11 cases in single center experience	Yang-Hyon Baek	Received

FRI-098	Phase I dose escalating study of hypoxia-activating agent tirapazamine in combination with trans-arterial embolization in patients with intermediate stage hepatocellular carcinoma	Nadine Abi-Jaoudeh	Received

THU-098	Transarterial chemoembolizaton combined with sorafenib for intermediate-stage hepatocellular carcinoma: a window of tumor burden for survival benefit	Guohong Han	Received

THU-099	The malignant transformation of hepatocellular adenoma: experience of a French liver center	Christine Sempoux	Received

FRI-099	PET/CT findings using 18F-labeled galactose tracer (FDGal) vs. 18F-labeled glucose tracer (FDG) in patients with hepatocellular carcinoma	Kirstine Petrea Bak-Fredslund	Received

SAT-099	Utility of serum alpha-fetoprotein measurement with a cutoff of 20ng/mL in addition to ultrasound surveillance for hepatocellular carcinoma in patients with chronic hepatitis B - a regression discontinuity analysis	Yan-Zheng Daniel Lim	Received

FRI-100	EpCAM-positive circulating tumor cells as liquid biomarker for early micrometastases and HCC recurrence risk	Kornelius Schulze	Received

THU-100	Radiological assessments in patients with hepatocellular carcinoma following transarterial chemoembolization: can initial response independently predict the survival regardless of tumor load?	Guohong Han	Received

THU-101	Hepatocellular carcinoma diagnostic performance of liver imaging reporting and data system for contrast enhanced ultrasound and of quantitative contrast enhanced ultrasound	Cosmin Gabriel Cristea	Received

FRI-101	Analysis of the breath metabolome in patients with Hepatocellular carcinoma	Ghassoub Rifai	Received

SAT-101	Plasma micoRNA-21, 26a, and 29a-3p as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma	Soon Sun Kim	Received

SAT-102	A low incidence of hepatocellular carcinoma in patients with genotype 1b compensated cirrhosis treated with paritaprevir/ritonavir, ombitasvir and dasabuvir ± ribavirin in a tertiary center: a matter of better selection?	Stefan Chiriac	Received

THU-102	Plasma microvesicles levels can predict the development of hepatocellular carcinoma in patients with cirrhosis	Cristina Levi	Received

FRI-102	Regional differences in the presentation and management of patients with hepatocellular carcinoma by liver disease etiology	Ming-Lung Yu	Received

THU-103	Hand-foot-skin reaction of grade two or higher within sixty days as the best response criterion for survival prediction in hepatocellular carcinoma treated by sorafenib	Guohong Han	Received

FRI-103	Temporal trends in etiology of liver disease, tumor characteristics, and long-term survival of patients with hepatocellular carcinoma: results of a single-center U.S. cohort from 1997-2016	Pauline Nguyen	Received

SAT-103	Analysis of postprogression survival of patients with advanced hepatocellular carcinoma treated with sorafenib	Yoshiyuki Wada	Received

FRI-104	Activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis	Lei Ling	Received

SAT-104	Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience	Stefano Okolicsanyi	Received

THU-104	Close association of arrest-defective protein 1 (ARD1) overexpression with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma	Danbi Lee	Received

SAT-105	Hepatocellular carcinoma in elderly patients referred to a tertiary center with multidisciplinary team approach: clinical presentation and outcomes	Stefano Okolicsanyi	Received

SAT-106	Early changes in perfusion-computed tomography scan parameters as a marker of improved outcomes in patients with hepatocellular carcinoma treated with Sorafenib	Stefano Okolicsanyi	Received

FRI-106	Effect of novel AKT inhibitor ARQ 751 as single agent and its combination with sorafenib on hepatocellular carcinoma in a cirrhotic rat model	Kurma Keerthi	Received

FRI-107	Kangai 1 C-terminal interacting tetraspanin plays an important role in cholangiocarcinogenesis	Khac Cuong Bui	Received

THU-107	Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study	David James Pinato	Received

FRI-108	RNA sequencing of intrahepatic cholangiocarcinoma reveals two prognostic subclasses	Keun Soo Ahn	Received

SAT-108	Serum hepatocyte growth factor (HGF) is a potential marker for baseline liver function and its early deterioration in patients treated with sorafenib	Yutaka Yasui	Received

THU-108	CRIPTO expression in hepatocellular carcinoma	Danny van der Helm	Received

SAT-109	Identification of tumour suppressive and oncogenic microRNAs in gallbladder carcinoma	Stephanie Roessler	Received

FRI-109	PNPLA3 p.I148M risk allele carriers might be at-risk of chemotherapy- associated steatohepatitis (CASH)	Marcin Krawczyk	Received

THU-109	Intra-tumour heterogeneity in the regulation of immune-tolerogenic pathways in primary and metastatic hepatocellular carcinoma	David James Pinato	Received

FRI-110	Targeting tumour-stromal interactions – differential pharmacological modification of AMPK/mTORC1 in human hepatic stellate cells and hepatocellular carcinoma	Katrin Schölzel	Received

SAT-110	Kupffer cells as antigen-presenting cells in mouse livers with hepatocellular carcinoma	Stephanie Lacotte	Received

SAT-111	Oncostatin M induces increased invasiveness and angiogenesis in hepatic cancer cells through HIF1alpha-related release of VEGF-A	Stefania Cannito	Received

FRI-111	IMPDH exerts a tumor-suppressing role in hepatocellular carcinoma	Kan Chen	Received

THU-111	DPP4 inhibition reveals interleukin-33–dependent eosinophil-mediated tumor immunity in hepatocellular carcinoma	Clémence Hollande	Received

FRI-112	Hepatocyte nanodelivery using siRNA c-Jun N-terminal Kinase-2 (siJnk2) for the treatment of chronic liver disease	Marius Maximilian Woitok	Received

SAT-113	Impact of natural killer cells receptors gene haplotypes on the development of hepatocarcinoma in cirrhotic patients	Simona Onali	Received

THU-113	Role of RAS-dependent signaling pathways in hepatic carcinogenesis	Christian Lechler	Received

FRI-113	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification	Julien Calderaro	Received

THU-114	Hepatic tumour burden is reduced by endogenous overexpression of chemerin-157	Elisabeth Margareta Haberl	Received

SAT-115	Fatty liver binding protein 4: a targetable adipokine in hepatocellular carcinoma related to metabolic syndrome	Samira Laouirem	Received

THU-115	Preclinical evaluation of polyethylenimine-mediated RNA interference of Polo-Like Kinase 1 gene for ultrasound image-guided treatment of hepatocellular carcinoma	Eric Robinet	Received

FRI-115	Genetic and epigenetic bases of the relationship between reduced OCT1 expression and poor response to sorafenib in hepatocellular carcinoma and cholangiocarcinoma	Jose J.G. Marin	Received

FRI-116	IL6-dependent genomic instability Heralds accelerated carcinogenesis following liver regeneration on a background of chronic hepatitis	Jonathan H. Axelrod	Received

SAT-116	Metformin reduces cell migration and down-regulates epithelial to mesenchymal transition by AMPK / Foxo3a pathway in human intrahepatic cholangiocarcinoma	Sabina Di Matteo	Received

THU-116	Inhibition of lymph node metastasis by CTGF in Notch1 driven malignant transformation of rat liver oval cells	Chao Liu	Received

SAT-117	Molecular basis of natural killer cell dysfunction in hepatocellular carcinoma	Gabriele Missale	Received

FRI-117	Insulin/IGF-1 receptors mediate acquired resistance to anti-EGFR therapy in human cholangiocarcinoma cells	Javier Vaquero	Received

THU-117	Tumour suppressor SH2D4A is involved in endosomal trafficking of STAT3 in hepatocellular carcinoma cells	Carolin Ploeger	Received

FRI-118	Chromosomal aberrations are effected by transformation-related protein 53 deletion in inflammation induced hepatocarcinogenesis	Michael Svinarenko	Received

THU-118	Genetic differences in hepatocellular carcinoma among chronic persistent hepatitis B virus infection with or without viral suppression and prior hepatitis B virus infection	Fukiko Kawai-Kitahata	Received

SAT-118	DNA circulating free in patients with hepatocellular carcinoma	Valérie Dejour	Received

THU-119	Functional role of CCL5/RANTES for hepatocellular carcinoma progression during chronic liver disease	Antje Mohs	Received

FRI-119	Free fatty acids enhance CD36 knockdown in primary human hepatocytes and abrogate PTEN expression – recapitulation of NASH-associated HCC	Jan-Peter Sowa	Received

SAT-119	Fractalkine-CX3CR1 is the only predictor for mortality in hepatocellular carcinoma patients treated with curative radiofrequency ablation	Wei Teng	Received

FRI-120	Extracellular ATP and subsequent purinergic P2Y2 receptor signalling promote liver tumorigenesis in mice	Isabel Schulien	Received

THU-120	miR-22 deficiency fosters hepatic tumour development	Anne-Sophie Ay-Berthomieu	Received

SAT-120	Exome sequencing identifies a mutation associated with hepatocellular carcinoma development in hepatitis C virus infected individuals	Rodrigo Feliciano Carmo	Received

THU-121	Proteomic analysis identifies argininosuccinate synthase 1 as a useful biomarker for hepatocellular adenoma classification and patient management	Anne-Aurelie Raymond	Received

FRI-121	Rapamycin and zoledronic acid synergistically repolarize tumour associated macrophages towards anti-HCC responses	Misbah Aslam	Received

SAT-121	Identification of invasion-addicted genes driven by transforming growth factor-beta in hepatocellular carcinoma	Wolfgang Mikulits	Received

SAT-122	Integrated analysis of exosomal microRNA, gene, and pathway regulatory networks in fibrosis and hepatocarcinogenesis	Robert Cheng	Received

THU-122	RIPK1 suppresses a TRAF2-dependent pathway to liver cancer	Tom Luedde	Received

SAT-123	Liver-targeting with the novel nucleotide prodrug MIV-818 designed for the treatment of liver cancers	Richard Bethell	Received

FRI-123	Molecular characterization of the immune class of hepatocellular carcinoma	Iris Martinez-Quetglas	Received

THU-123	A small number of senescent hepatocytes is sufficient to attenuate liver regeneration and enhance tumorigenesis	Anna Potapova	Received

THU-124	Cerium oxide nanoparticles display anti-tumoral activity and improve survival in experimental hepatocellular carcinoma	Guillermo Fernandez-Varo	Received

FRI-124	TGF-ß oncogenic pathway in HCC: PMEPA1 as a biomarker of treatment response	Iris Martinez Quetglas	Received

SAT-124	VEPH1 regulates the occurrence and development of hepatocellular carcinoma by affecting the PI3K/Akt/mTOR signal pathway	Pinging Dong	Received

FRI-125	Characterization of cancer associated fibroblasts in primary site and metaststic lymph nodes of intrahepatic cholangiocarcinoma by immunohistochmistry	Naoki Uyama	Received

THU-125	The absence of OCT1 at the plasma membrane of tumor cells is associated with a worse response of hepatocellular carcinoma to sorafenib	Johannes Weiss	Received

THU-126	A new in vitro hepatocellular carcinoma model based on human normal and fibrotic 3D extracellular matrix scaffold bio-engineering	Andrea Telese	Received

FRI-126	Selenoenzyme glutathione peroxidase 4 affects profile of infiltrating immune cell in hepatocellular carcinoma	Nataliya Rohr-Udilova	Received

SAT-126	CCL2-dependent monocyte recruitment contributes to a tumor-promoting microenvironment in a combined fibrosis-HCC model	Peter Leonard Schrammen	Received

SAT-127	CCAAT/Enhancer Binding Protein Delta exerts tumor-supportive effects but is down-regulated in patient hepatocellular carcinoma	Pengyu Liu	Received

FRI-127	Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib	Hyo Jung Cho	Received

THU-127	microRNA-34a and natural killer cells: an immuno-epigenetic approach to halt hepatocellular carcinoma progression	Amira Khaled Abdelhamid	Received

THU-128	The anti-inflammatory receptor TREM-2 protects the liver from hepatocellular carcinoma development	Aitor Esparza-Baquer	Received

FRI-128	Overexpression of arrest-defective protein 1 in dysplastic hepatic nodule as a possible marker of malignant potential	Hyo Jeong Kang	Received

FRI-129	Liver microRNA hsa-miR-125a-5p may exert an oncosuppressor effect on HCC	Nicola Coppola	Received

SAT-129	Distinct features of early and late-stage liver cancer cells correlate with their response to metabolic perturbation	Zeribe Nwosu	Received

THU-129	Chronic treatment with over-the-counter H1 or H2 histamine receptor blockers decreases cholangiocarcinoma xenograft tumor growth, angiogenesis and EMT	Heather Francis	Received

THU-130	Effect of hepatitis E virus infection on the human hepatic innate immune response in human liver chimeric mice	Ibrahim M. Sayed	Received

FRI-130	Prevalence and risk factors for hepatitis B infection in the adult population of Georgia: a nationwide survey	Ana Kasradze	Received

FRI-131	Interferon-free antiviral therapy does not increase the risk of developing short term hepatocellular carcinoma in patients with cirrhosis infected with hepatitis C virus	Andrea Nuñez	Received

SAT-131	AKT inhibitor ARQ 092 and sorafenib additively inhibit progression of hepatocellular carcinoma and improve immune system in cirrhotic rat model	Zuzana Macek Jilkova	Received

FRI-132	Prevalence of anti-HEV antibodies among patients with immunosuppression and hepatic disorders	Anna Parfieniuk-Kowerda	Received

THU-132	Common polymorphisms in the TLR3 gene are stronger associated with spontaneous clearance of Hepatitis B virus infection in caucasians than variants of the HLA gene	Janett Fischer	Received

THU-133	Identification of serum metabolite profiles associated with the risk of developing hepatitis B-related hepatocellular carcinoma using metabolomics	Jia-Kai Hsu	Received

FRI-133	In HBeAg-negative chronic HBV infection, HBsAg levels profoundly vary among different HBV-genotypes and can be influenced by the degree of HBsAg variability: can quantitative HBsAg truly reflect intra-hepatic HBV reservoir?	Arianna Battisti	Received

SAT-133	Incidence and mortality of viral hepatitis in China	Mingyuan Zhang	Received

FRI-134	Mother-to-child transmission of hepatitis B virus in Ethiopia	Asgeir Johannessen	Received

THU-134	Serum hepatitis B core antibody as a novel tool to assess hepatic inflammation guide antiviral decision-making in chronic hepatitis B patients with normal alanine aminotransferase levels	Jiyuan Zhou	Received

SAT-134	Re-evaluation of chronic hepatitis B patients lost to follow-up: results from the northern holland retrieval project	Nina Beekmans	Received

THU-135	Progesterone receptor mutations predisposes to HEV infection in the HIV-positive host	Jose Daniel Debes	Received

FRI-135	Clinical outcomes were comparable between chronic hepatitis B patients with virological response using oral antiviral therapy and inactive carriers when adjusting for fibrotic burden	Beom Kyung Kim	Received

SAT-136	Noninvasive models to predict liver fibrosis in patients with chronic hepatitis B: a study from Turkey	Pinar Korkmaz	Received

THU-136	Correlation of hepatitis B virus genomic variants with HBsAg Titers and HBV-DNA levels in a large European study cohort of patients with chronic hepatitis B	Kai-Henrik Peiffer	Received

SAT-137	Clinical significance of post-liver transplant hepatitis E seropositivity in high prevalence area of genotype 3: interim result of 8-month prospective follow-up study	Piyawat Komolmit	Received

FRI-137	Association between mutations on the basal core promoter region and hepatocellular carcinoma in Vietnamese chronic hepatitis B patients	Cam Huong Thi Nguyen	Received

THU-138	Impact of chronic liver disease on the survival of patients hospitalized with acute hepatitis A infection: nationwide hospital admission data from Thailand	Kittiyod Poovorawan	Received

SAT-138	A five-year single centre experience of hepatitis E virus infection during pregnancy from New Delhi	Premashis Kar	Received

FRI-138	2´-C-methylcytidine inhibits hepatitis E virus replication but antagonizing ribavirin	Changbo Qu	Received

SAT-139	The circulation of specific vaccine-escape HBsAg mutations in HBV genotype D infected patients correlates with high viremia and affects HBsAg detection and quantification	Lorenzo Piermatteo	Received

THU-139	A nationwide seroprevalence of hepatitis a in Republic of Korea from 2005 to 2014, before and after peak outbreak in 2009	Sook-Hyang Jeong	Received

FRI-139	Phenotypic and genotypic shifts of hepatitis B virus in treatment naïve patients following extensive use of antivirals in a chronic hepatitis B endemic area	Chau-Ting Yeh	Received

SAT-140	Poor adherence to hepatitis B screening protocols prior to rituximab; a multicentre South Australian study	Alan Wigg	Received

FRI-140	Identificaiton of an hot integration area for hepatitis B viral genome in the tenth intron of DEP Domain-Containing 5 gene in hepatoma patients with unfavorable postoperative prognosis	Chau-Ting Yeh	Received

THU-140	Hepatitis E virus infection and ribavirin treatment in patients with chronic lymphocytic leukemia receiving ibrutinib	Laurent Alric	Received

THU-141	The pro-inflammatory CD161+CD4+ T cells were recruited to liver through C-X-C motif chemokine receptor 6 (CXCR6)-C-X-C motif chemokine ligand 16 (CXCL16) and CX3CR1-CX3CL1 axes during chronic hepatitis B	Li-Sha Cheng	Received

FRI-141	Increased natural killer cell function after structured interruption of long-term nucleos(t)ide analogue therapy is associated with active hepatitis	Christine Lea Zimmer	Received

SAT-141	A territory-wide study on the seroprevalence of hepatitis B and C virus in the general population in Hong Kong, China	Sze Hang Kevin Liu	Received

THU-142	Hepatitis Delta Antigen (HDAg) is characterized by an extensive degree of genetic variability that correlates with elevated levels of serum HDV-RNA	Luna Colagrossi	Received

THU-143	Nucleos(t)ide analogue decreased liver stiffness of e-antigen negative chronic hepatitis B (CHB) patients over a 10-year interval	Lung-Yi Mak	Received

FRI-143	Characterization and evaluation of hepatic fibrosis degree in patients with chronic hepatitis B virus infection with normal transaminases	Cristina San Juan	Received

SAT-143	Identifying true inactive HBV carriers using fibrosis-4 index	Tai-Chung Tseng	Received

THU-144	Absence of hepatitis B reactivation among veterans with serological evidence of previous hepatitis B infection receiving anti-hepatitis C direct acting antivirals	Lydia Tang	Received

SAT-144	Anti-HEV seroprevalence rate in the Americas	Thomas Horvatits	Received

FRI-144	Frequent delayed hepatitis B surface antigen spontaneous clearance among high risk groups	Daniela K van Santen	Received

FRI-145	The value of subtyping genotype A in chronic hepatitis B: differences in disease course and implications for therapy	Enoka Gonsalkorala	Received

SAT-145	Further evaluation of the RoboGene Kit for HDV RNA quantification including viral load monitoring under therapy and performance in different genotypes	Ute Hofmann	Received

THU-145	Prevalence, determinants of chronic hepatitis B infection and hepatitis B genotypes in multi-ethnic Suriname	M. Sigrid. Mac Donald - Ottevanger	Received

THU-146	hepatitis C virus hepatitis B virus co-Infection disproportionately worsens cirrhosis, hepatic decompensation, and hepatocellular carcinoma incidence in Non-Asians as compared to Asians	Pauline Nguyen	Received

SAT-146	Gain of positively charged amino acids at specific positions of HBsAg C-terminus tightly correlates with HBV-induced hepatocellular carcinoma by altering the structural folding of this domain	Valentina Svicher	Received

FRI-146	Liver transient elastography (Fibroscan©): performance for the absolute mortality and clinical disease progression risk evaluation in chronic hepatitis C	Fatima Serejo	Received

SAT-147	Potential implications of detecting Hepatitis B surface antigen in asymptomatic people in an endemic community through medical camps	Varun Gupta	Received

THU-148	Transient elastography evolution in non treated patients with chronic hepatitis B (CHB) infection	Maria Luisa González-Diéguez	Received

SAT-148	Hepatitis E virus activates signal transducer and activator of transcription 3 to facilitate viral replication	Wenshi Wang	Received

THU-149	Clinical and virological outcomes of hepatitis B virus inactive carriers and gray zone patients: a comparative analysis using current EASL and AASLD Guidelines criteria	Martin Sebastian Bonacci	Received

SAT-149	A revisit of anti-HBc IgM in the differentiation of acute HBV infection from chronic HBV infection with acute flare-up	Yi-Cheng Chen	Received

SAT-150	Development and validation of a simple score to select HBV-infected patients for antiviral therapy in Africa	Yusuke Shimakawa	Received

FRI-150	Tenofovir, entecariv and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B	Jung Gil Park	Received

THU-150	Liver histologic spectrum in hepatitis B virus patients co-infected with the human immunodeficiency virus	Mauricio Lisker-Melman	Received

SAT-151	Virally suppressed patients with chronic HBV infection without cirrhosis have better patient-reported outcomes (PROS)	Zobair M Younossi	Received

THU-151	Validation of the PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir	Mi Na Kim	Received

THU-152	Outcome in chronic hepatitis delta: differences between African and non-African patients	Ivana Carey	Received

SAT-152	PD-1+ CD8+ T cells as immunological biomarkers for the safe discontinuation of anti-viral therapy in chronic hepatitis B	Nina Le Bert	Received

FRI-152	No changes in the coding sequence for HBV core protein after 6 weeks of treatment of HBV infected humanized mice with NVR 3-778	Angela LAM	Received

THU-153	Serum cholinesterase: A predictive biomarker of hepatic reserves in patients with chronic Hepatitis D	Z Abbas	Received

THU-154	Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naïve caucasian patients with chronic HBeAg negative HBV infection	Andrew Vaillant	Received

FRI-154	Characterization of the intrahepatic immune response of virally-suppressed chronic hepatitis B patients to treatment with the oral TLR7 agonist GS-9620	Lauke Boeijen	Received

SAT-154	Characterization of hepatitis delta infection in Israel: prevalence and genotypes	Orna Mor	Received

FRI-155	An algorythm including quantitave HBsAg and HBcrAg is useful for discrimation between hepatitis B virus inactive carriers and patients with active chronic hepatitis B HBeAg negative	Mar Riveiro Barciela	Received

THU-155	Absence of mutations in the HBsAg "a" determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol	Andrew Vaillant	Received

SAT-155	A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B	Patricia Mendez	Received

THU-156	Post-entry antiviral effects of nucleic acid polymers against hepatitis B virus infection in vitro	Andrew Vaillant	Received

SAT-156	High rates of renal tubular damage in HBV monoinfected patients long-term treated with Tenofovir: a cross-sectional, single center, real-life study in 414 patients	Pietro Lampertico	Received

SAT-157	Minimal increases of alpha-fetoprotein above the normal value strongly predict HCC development in compensated Caucasian HBV cirrhotics treated by entecavir or tenofovir: a 7-year longitudinal cohort study in 225 patients	Pietro Lampertico	Received

FRI-158	Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection	Meifang Han	Received

THU-158	A novel mid-scale screening assay to identify compounds with anti-HDV activity	Bettina Buchmann	Received

FRI-159	Baseline serum WFA+-M2BP level is a strong predictor of response to pegylated interferon-a in HBeAg-positive chronic hepatitis B patients	Mingyu Zhu	Received

SAT-159	Kinetics of serum HBsAg and HBcrAg in predicting response to pegylated interferon-based therapy in patients with HBeAg-negative chronic hepatitis B	Pisit Tangkijvanich	Received

FRI-160	Next generation sequencing identifies baseline HBV mutants associated with treatment response to pegylated interferon in patients with HBeAg-positive chronic hepatitis B	Natthaya Chuaypen	Received

THU-160	Prediction of hepatitis B virus reactivation in lymphoma patients with resolved hepatitis B virus infection who received rituximab-containing chemotherapy: the roles of antiHBc/antiHBs quantification	Chiun Hsu	Received

FRI-161	Quantification of serum hepatitis B core-related antigen to understanding the hepatitis B virus and hepatitis D virus chronic infection	Alicia Ruiz-Ripa	Received

FRI-162	PreS1/PreS2/S and precore/core mutations related with major risk of hepatocellular carcinoma in patients with "grey-zone" chronic hepatitis B	Ana Isabel Gil	Received

THU-162	On-treatment decline in HBeAg level at week 24 predicts for HBeAg seroconversion during long-term tenofovir therapy for HBeAg-positive CHB	Darren Wong	Received

THU-163	On-treatment ALT flares are associated with HBsAg loss in genotype A chronic hepatitis B-infected patients treated with nucleotide analogue therapy	Darren Wong	Received

FRI-163	Increased hepatitis B virus (HBV) specific IFN- ? and IL17A secretion by T cell subsets in HBV infected non transmitting mothers and their HBV negative new-borns: A Novel mechanism for prevention of HBV vertical transmission	Nirupma Trehanpati	Received

SAT-164	Addition of (pegylated) interferon to entecavir increases response in treatment naïve HBeAg-positive patients with chronic hepatitis B	Seng Liem	Received

THU-164	Superior suppression of hepatitis B virus DNA and antigen levels in a chimeric mouse model when BB-103, a DNA-directed RNA interference agent, is coupled with standard of care drugs	David Suhy	Received

THU-165	Sequential combination therapy with IFN, rhIL-2 and therapeutic vaccine enhanced HBsAg loss in entecavir-suppressed CHB patients (the Endeavor study): an interim analysis	Di Wu	Received

SAT-165	Sustained efficacy and surface antigen seroconversion in the woodchuck model of chronic hepatitis B with the selective toll-like receptor 8 agonist GS-9688	Simon P. Fletcher	Received

FRI-165	A new HDV mouse model showing important features of human infection and identifying MAVS as a key player in IFN-ß induction	Carla Usai	Received

FRI-166	Hepatitis B virus quasispecies complexity is lower in hepatitis B virus–hepatitis D virus infection than in hepatitis B virus monoinfection	Cristina Godoy	Received

SAT-166	Three-year efficacy and safety of tenofovir disoproxil fumarate monotherapy for multidrug-resistant chronic hepatitis B	So Young Kwon	Received

THU-166	Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B	Pietro Lampertico	Received

SAT-167	Antiviral efficacy of a novel hepatitis B virus expression inhibitor in combination with entecavir and wIFN-alpha in woodchucks model of chronic hepatitis B	Steffen Wildum	Received

FRI-167	Identification of hepatitis B X protein regions responsible for the regulation of HBV transcription via histone modification	Danny Ka Ho Wong	Received

FRI-168	Proteomic profiling of plasma proteins associated with spontaneous hepatitis B surface antigen seroclearance in chronic hepatitis B	Fen Liu	Received

SAT-168	In vitro and in vivo characterization of the selective toll-like receptor 8 agonist GS-9688	Stephane Daffis	Received

THU-169	Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology	Gian Paolo Caviglia	Received

SAT-170	Hepatic steatosis via controlled attenuation parameter measurements and diabetes contribute to persistent liver fibrosis in the era of long-term nucleoside analogue therapy for chronic hepatitis B	Wai-Kay Seto	Received

FRI-170	The NLRP3 inflammasome is activated in liver tissue of patients with newly diagnosed chronic hepatitis B virus infection	Georgios Germanidis	Received

FRI-171	Viral Dominance patterns in hepatitis delta patients are associated with distinct systemic inflammatory patterns which influence response to interferon therapy	Gunnar Lewon Lutterkort	Received

FRI-172	Prediction for the incidence of hepatocellular carcinoma in patients with chronic hepatitis B after administration of nucleos(t)side analog	Hideaki Takahashi	Received

SAT-172	Predictors for clinical relapse within 2 year off-ETV therapy in HBeAg negative chronic hepatitis B patients	Wen-Juei Jeng	Received

THU-172	Experiences from one of the largest treatment programs for chronic hepatitis B in sub-Saharan Africa	Hailemichael Desalegn	Received

THU-173	Nucleic acid polymer REP2139 monotherapy reveals a short half-life of serum HBsAg in HBeAg+ chronically infected hepatitis B virus patients	Andrew Vaillant	Received

SAT-173	Revisit HBsAg for HBeAg-negative chronic hepatitis B undergoing peginterferon treatment: a multicenter pooled-analysis study	Yin Chen Wang	Received

FRI-173	Relationship between HBsAg, HBV DNA, covalently closed circular DNA and fibrosis stage in chronic HBV (HBeAg-negative) patients	Konstantin Kozlov	Received

SAT-174	Reduced hepatitis B and D viral entry using novel clinically-applied inhibitors of the sodium taurocholate co-transporting polypeptide	Joanne Donkers	Received

FRI-175	High rate of progression to cirrhosis in patients with chronic hepatitis B (CHB) and non-alcoholic fatty liver (FL)	Jie Li	Received

THU-175	Baseline and early on-treatment HBsAg level to predict HBsAg loss in nucleotide analog suppressed and HBeAg cleared chronic hepatitis B patients by switching to peginterferon alfa-2a: exploratory results of NEW SWITCH study	Hong Ren	Received

SAT-175	Comparison of HDV mono-infection with genotype 1 and 3 in CRPISPR/Cas generated humanized NTCP mice and human liver chimeric mice	Katja Giersch	Received

FRI-176	Injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study	Evan Brian Cunningham	Received

SAT-176	Serum HBV pgRNA can serve as clinical marker for cccDNA activity in patients with HBV mono and HBV/HDV co-infection	Lena Allweiss	Received

THU-176	A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population	James Hamilton	Received

SAT-177	An early step of Hepatitis B virus infection is dependent on the nuclear receptor for bile acids, farnesoid X receptor alpha	Patrice Andre	Received

FRI-177	Community pop-up clinic: a harm reduction strategy to engage hepatitis C virus infected injection drug users	Ghazaleh Kiani	Received

FRI-178	Evaluation of a sequence-based method for hepatitis C genotyping (Deepchek SingleRound PCR and NS5B/5´UTR sequencing) and comparison with VERSANT HCV Genotype 2.0 assay (InnoLiPA)	Greet Boland	Received

SAT-179	Hepatitis B Virus infection alters the transcriptional regulation of FXR-dependent microRNAs	Philipp Fritze	Received

THU-179	Enhancing detection and treatment of chronic hepatitis C related liver disease in vulnerable adults through a dedicated homeless hostel-based liver service: Vulnerable Adults LIver Disease Study	Ahmed Hashim	Received

FRI-179	Integrated healthcare system implementation of one time hepatitis C virus testing for patients born between 1945 and 1965 with linkage to care	James M Levin	Received

THU-180	Change in the trajectory of MELD scores in liver transplant candidates with hepatitis c in the direct acting antiviral era	Allison Kwong	Received

FRI-180	Late presentation of patients with chronic hepatitis C	Janne Fuglsang Hansen	Received

SAT-180	CRV431 and CMX157: Anti-HBV combination effects in vitro between a cyclophilin inhibitor and a nucleotide prodrug	Robert Thomas Foster	Received

SAT-181	The cyclophilin inhibitor CRV431 prevents both cyclophilin A-HBx complex formation and HBV replication	Robert Thomas Foster	Received

FRI-181	A behavioral Intervention improves the rate of hepatitis C treatment initiation among HIV/HCV coinfected patients: results of a randomized controlled trial	Jeffrey J Weiss	Received

THU-181	Interferon lambda 4 CC host genetic variant is linked with spontaneous hepatitis C virus clearance for genotypes 1, 2, and 3	Anders Widell	Received

SAT-182	Hepatitis B virus X RNA is present in cell culture-derived virus preparations and plasma from chronically infected patients	Rudolf Beran	Received

FRI-182	Linkage to care of HBsAg and anti-HCV positive patients after a systematic screening approach in the German primary care setting	Johannes Wiegand	Received

THU-182	Declining prevalence and increasing awareness of hepatitis C virus infection in Italy: A population-based survey	Antonio Massimo Ippolito	Received

SAT-183	Hepatic expression of oncogenes Bmi1 and Dkk1 can be induced by treatment with Hepatitis B virus particles or Lipopolysaccharide in vitro and is up-regulated in liver biopsies of patients with chronic HBV infection	Ruth Broering	Received

FRI-183	Population level outcomes and cost-effectiveness of expanding guidance for age-based hepatitis C testing in the United States	Joshua A Barocas	Received

THU-183	Aerobic exercise and physical activity interventions in the management of hepatic manifestations of chronic hepatitis C; a systematic review	Ann Marie Monaghan	Received

THU-184	An assessment of physical activity levels and cardiorespiratory fitness in individuals living with hepatitis C	Ann Marie Monaghan	Received

FRI-184	CHESS - curing hepatitis C: effect on the endothelium and cardiovascular risk	Joshua S Davis	Received

SAT-184	Insulin enhances HBV replication and interferes with antiviral activity of IFN-a	Sandra Marie-Ange Phillips	Received

SAT-185	Early function modulation and reprogramming of Kupffer cells promote establishment and maintenance of HBV infection	Suzanne Faure-Dupuy	Received

THU-185	High-risk behaviour in a cohort of HIV/hepatitis C coinfected gay and bisexual men commencing hepatitis C treatment	Joseph S Doyle	Received

THU-186	Expression of NK cell receptors in childhood malignancy survivours in children with chronic hepatitis C	Anna Mania	Received

SAT-186	Peripheral and intrahepatic virological phenotyping in eAg negative chronic hepatitis B to evaluate risk of disease progression and hepatocellular carcinoma in the "grey-zone" viral load cohort	Valentina Svicher	Received

FRI-186	Treatment of chronic hepatitis C virus (HCV) infections with direct acting antivirals in the New Mexico state prison system using the project ECHO model	Karla Thornton	Received

THU-187	Low hepatitis C virus prevalence among human immunodeficiency virus+ individuals in Sub-Saharan Africa	Anne Loarec	Received

SAT-187	Hepatitis B virus production is enhanced through early autophagic flux but degraded through autophagosome-lysosome fusion	Yong Lin	Received

FRI-188	IL6-174GG genotype is associated with diabetes mellitus type 2 in patients with chronic hepatitis C	Luciana Diniz Diniz Silva	Received

THU-188	Hepatitis B testing in a large cohort of U.S. hepatitis C virus -infected patients	Anne C Moorman	Received

SAT-188	impact of long-term tenofovir disoproxil fumarate treatment on bone metabolism and skeletal muscle function in mouse	Yu-Xuan Luo	Received

SAT-189	The e antigen of the Hepatitis B virus enables evasion of Type 1 Interferon immune response	Zina Valaydon	Received

FRI-189	Muscle mass is a protector factor against low bone mineral density in hepatitis C	Luciana Diniz Silva	Received

THU-189	An audit of hepatitis C screening and referral patterns to a specialist hepatology service in a secondary care facility in the UK	Anthony Pratt	Received

FRI-190	Long-term fibrosis improvement after sustained virologic response in patients with chronic hepatitis C and advanced fibrosis or cirrhosis - pre-treatment cirrhosis, older age and high body mass index increases the risk for persisting fibrosis	Magnus Hedenstierna	Received

SAT-190	Determinants of the future burden of hepatocellular carcinoma after eradication of hepatitis C virus among cirrhotic patients	Prowpanga Udompap	Received

THU-190	Prevalence of hepatitis C in the spanish population. the prevhep study (ethon cohort)	Antonio Cuadrado Lavin	Received

THU-191	High incidence of persistently altered liver tests after sustained virological response with direct-acting antiviral in hepatitis C monoinfected and HIV-coinfected patients	Antonio Olveira	Received

SAT-191	The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients	Rachna Shridhar	Received

FRI-191	Survival in patients with chronic hepatitis C and mild-moderate fibrosis according to antiviral treatment response	Marc Puigvehí	Received

FRI-192	An approach to hepatitis C Virus epidemiology: analysis in 7602 patients of orthopaedic surgery	Maria Pipa-Muniz	Received

SAT-192	Prevalence of thyroid dysfunction among 21672 Egyptian patients with chronic HCV genotype IV	Zeinab Abdellatif	Received

FRI-193	A framework for hepatitis C virus treatment as prevention in the prison setting: the SToP-C implementation toolkit	Marianne Byrne	Received

THU-193	HCV-infected people who inject drugs (PWID): engagement in care and treatment, and prevention of reinfection	Arshia Alimohammadi	Received

FRI-194	DAA treatment scale-up in HIV/HCV co-infection: Characterisinga population at risk for reinfection	Marianne Martinello	Received

THU-194	Large-scale screening is not useful to identify individuals with hepatitis B or C virus infection: results of an interim analysis	Astrid Marot	Received

SAT-194	Low rates of hepatitis C virus (HCV) testing and HCV awareness among individuals at high risk for chronic HCV infection among an underserved safety-net population	Robert Wong	Received

FRI-195	Can HCV core antigen replace HCV RNA testing in the era of direct-acting antivirals?	Marjolein Van Tilborg	Received

THU-195	Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: The SToP-C study	Behzad Hajarizadeh	Received

SAT-195	Impact of cryoglobulinemia on HCV viral load measurements of different molecular diagnostic systems	Gian Maria Prati	Received

FRI-196	Can dried blood spots be used for diagnosis of chronic hepatitis C virus infection, even if they are stored under non-ideal conditions?	Marjolein Van Tilborg	Received

SAT-196	Validation of the role of FIB-4 and APRI in the assessment of hepatic fibrosis and prediction of risky varices in Egyptian patients with chronic hepatitis C (genotype 4)	Saeed M. El-Nahaas	Received

THU-196	Injecting heroin - how long until hepatitis C infection obtained?	Brian Stephens	Received

FRI-197	Association between improved liver function and selenium depends on C718T polymorphism in 3´- untranslated region of glutathione peroxidase 4 and in humans	Nataliya Rohr-Udilova	Received

SAT-197	Abnormal microvasculature in chronic viral hepatitis	Samantha Sarcognato	Received

FRI-198	The impact of sustained virological response on long term risk of decompensated cirrhosis: the BC hepatitis testers cohort	Naveed Z. Janjua	Received

THU-198	Cross-sectional assessment of >20,000 clinical samples submitted for HCV NS3/4A protease inhibitor drug resistance testing in the US	Jacqueline Reeves	Received

THU-199	The number of small low-density lipoprotein particles is decreased by hepatitis C virus G1b infection	Chika Kinoshita	Received

FRI-199	Abbott HCV core Ag and HCV RNA comparison study in country of Georgia	Nazibrola Chitadze	Received

SAT-199	Predictors of minimal hepatic encephalopathy in asymptomatic HCV patients before and after antiviral treatment: preliminary results from the EMERALD study	Sharon Levy	Received

SAT-200	Hepatocellular Carcinoma in Patients with Chronic Hepatitis C and Cirrhosis in Denmark	Sofie Hallager	Received

FRI-200	Trends in hepatitis C-related mortality in Switzerland	Francesco Negro	Received

THU-200	High prevalence of concomitant substance abuse and mental health disorders in an urban underserved FQHC-based hepatitis C virus treatment program	Christian Boyd Ramers	Received

SAT-201	Gender differences on long-term outcomes in patients with dual chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infection	Pauline Nguyen	Received

THU-201	Diversity of the association of serumlevelsand genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C	Chung-Feng Huang	Received

SAT-202	Impact of amino acid substitutions of HCV core region on hepatocarcinogenesis and hepatocellular oxidative stress in HCV infection	Takeshi Chida	Received

FRI-202	Gender differences in liver disease progression by ethnicity in patients with chronic hepatitis C virus (HCV) mono-infection	Pauline Nguyen	Received

THU-202	Characterisation of resistance associated substitutions in direct acting antivirals treatment naive patients with genotype 3 hepatitis C virus	David Anthony Smith	Received

THU-203	Prevalence and genotype distribution of hepatitis C virus in Georgia: a 2015 nationwide population-based survey	Davit Baliashvili	Received

FRI-203	Epidemiology and treatment of hepatitis C virus infection in China in 2013-2015: a hospital-based population study	Peng Hu	Received

FRI-204	TM6SF2, MBOAT7 and PNPLA3 genotypes in patients with untreated HCV chronic hepatitis and alcohol intake	Pietro Lampertico	Received

SAT-204	Resistance analysis in the MAGELLAN-1 Study (Part 2): Glecaprevir/pibrentasvir therapy in HCV-infected patients who had failed prior DAA regimens containing NS3/4A protease and/or NS5A inhibitors	Tami Pilot-Matias	Received

THU-204	Understanding factors associated with hepatitis c spontaneous viral clearance: a meta-analysis	Dewi Nur Aisyah	Received

FRI-205	Pooled resistance analysis in HCV genotype 1-6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials	Preethi Krishnan	Received

THU-205	Search for anti-hepatitis C virus positive patients lost in the health system: analysis of the absence of referring and the abandonment of the patient	Elena Martinez Crespo	Received

THU-206	Rate and predictive factors of spontaneous hepatitis C virus clearance after acute infection in human immunodeficiency virus-positive subjects	Emanuela Messina	Received

SAT-206	Field evaluation of Xpert HCV Viral Load point-of-care test for detection of hepatitis C virus infection by venipuncture-collected and finger-stick capillary whole-blood samples	Tanya Lynn Applegate	Received

FRI-206	A novel single daily fixed dose combination of sofosbuvir 400 mg + ribavirin1000 mg + egcg 400 mg is superior to the standard of care as an anti-viral and safer causing less hemolysis in patients with chronic hepatitis C	Gamal Shiha	Received

SAT-207	Hepatitis C virus core antigen and dried blood spots as simplified hepatitis C virus diagnostic tools	Tanya Lynn Applegate	Received

FRI-207	Active versus passive follow-up examination of patients with chronic hepatitis C during Sofosbuvir/Ledipasvir treatment	Ganbolor Jargalsaikhan	Received

FRI-208	Rapid liver fibrosis regression after sustained virological response in HCV patients treated with direct acting antivirals	Gema Maria Lledó Ibáñez	Received

SAT-208	Correlation between prevalence of hepatitis B and C virus infection and mortality of hepatocellular carcinoma in Uvs province, Mongolia	Uurtsaikh Baatarsuren	Received

THU-208	Performance of the validated EGCRISC screening tool in chronic hepatitis C infection detection after application in the Egyptian setting	Engy Mohamed El-Ghitany	Received

THU-209	In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with daas is related to decline in liver inflammation	Adam Winters	Received

SAT-209	Drop of FGF19 levels in patients with HCC development following DAA therapy for chronic hepatitis C	Vanessa Stadlbauer	Received

FRI-209	Platelets represent an independent predictor of sustained virological response (SVR) in patients with advanced chronic hepatitis C (CHC) treated with current direct acting antiviral(s) (DAA). HERACLIS: Hellenic multicenter real-life cohort study	George Papatheodoridis	Received

THU-210	Factors that influence the improvement of serum albumin during interferon-free sofosbuvir/ledipasvir therapy for Japanese patients with chronic hepatitis C virus infection	Akira Kawano	Received

SAT-210	Regeneration linked miRNA in acute liver failure can predict clinical recompensation after DAA associated HCV cure: a novel biomarker to inform treatment ion in decompensated HCV cirrhosis?	Siamak Salehi	Received

FRI-210	An outbreak of acute hepatitis C GT1b in onco-hematological patients. Treatment with Sofosbuvir+Ledipasvir and concomitant chemotherapy	Giovanni Battista Gaeta	Received

FRI-211	Direct Acting Antivirals in patients with HCV-associated mixed cryoglobulinemia: real life safety and efficacy	Monica Schiavini	Received

SAT-211	Impact of genotype 3 on clinical outcome in patients with hepatitis C: both diabetes meliitus and liver disease progression	Wayel Zanjir	Received

SAT-212	Hepatitis C: Awareness Through to Treatment (HepCATT) study: Evaluation of an intervention designed to increase diagnosis and treatment of patients with hepatitis C virus infection in drug treatment settings	Matthew Hickman	Received

FRI-212	DAA-based treatment in HCV and HIV/HCV co-infected patients in real world: data from a large single-centre experience	Michele Milella	Received

THU-212	Markedly improvement of glycaemic control in diabetic patients with chronic hepatitis C achieving sustained virologic response after direct acting antiviral therapy: results of a prospective controlled study	Alessia Ciancio	Received

SAT-213	Successful Hepatitis C treatment with direct acting antivirals leads to a rapid on-treatment decrease of liver stiffness with a slower gradual decrease of spleen stiffness	Wim Verlinden	Received

THU-213	Impact of IL28B genotype on response rates in hepatitis C virus cirrhotic patients treated with new DAA regimens: experience of a single center	Paola Ponzo	Received

THU-214	Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone	Alison Boyle	Received

SAT-214	Epidemiology of hepatitis C infections in patient population in Northeastern China: a cross-sectional study	Yue Hu	Received

FRI-214	Real world outcomes of DAA therapy for chronic hepatitis C virus infection in the HCV Research UK National cohort	Michelle Cheung	Received

SAT-215	Elevated serum wisteria floribunda agglutinin-positive mac-2-binding protein levels associated with risks of diabetes and end-stage renal diseases among patients with hepatitis C virus infection	Yu-Ju Lin	Received

THU-215	Risk of cardiovascular and cerebrovascular events in hepatitis C patients following completion of direct-acting antiviral therapy: a retrospective cohort study	Anand P. Chokkalingam	Received

THU-216	Persistence of hepatitis c virus core antigenemia after sustained virological response is associated with worsening of liver function and increased risk of hepatocellular carcinoma	Amr Shaaban Hanafy	Received

SAT-216	The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: real-world evidence from the United States	Yuri Sanchez Gonzalez	Received

FRI-216	Sofosbuvir/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: an interim analysis on safety, efficacy and impact on quality of life	Guia Cerretelli	Received

FRI-217	Modeling vaccine and DAA treatment scale up effect on hepatitis C prevalence among persons who inject drugs in metropolitan Chicago	Harel Dahari	Received

SAT-217	Extra-hepatic manifestations from hepatitis C virus infection related to female infertility and adverse pregnancy outcomes: A real-world observation	Yuri Sanchez Gonzalez	Received

THU-217	SVR reduces ethnic disparities in progression to advanced liver disease in patients with chronic hepatitis C	An K. Le	Received

THU-218	Risk of hepatitis B virus reactivation during exposure to hepatitis C virus treatment: an analysis of US ambulatory electronic medical record data	Anand P. Chokkalingam	Received

SAT-218	Health-related quality of life in children with hepatitis C viral (HCV) infection treated with Sofosbuvir and Ribavirin	Zobair M Younossi	Received

FRI-218	Sofosbuvir-based therapy in patients with chronic hepatitis C virus infection and malignancies – a prospective observational study of 136 patients	Harrys Antonio Torres	Received

SAT-219	Significant incidence of psyquiatric disorders despite rapid and positive impact of direct acting antivirals on quality of life	Zoe Mariño	Received

THU-219	Efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir plus/minus ribavirin for treatment of hepatitis C virus genotype 1b compensated cirrhosis in patients aged 70 years or older	Anca Trifan	Received

FRI-219	Full dose, daily sofosbuvir treatment in end-stage renal disease: tolerability & safety of largest ESRD patient cohort exposed to this drug	Hector Enrique Nazario	Received

FRI-220	Excellent cure rates in largest ESRD patient cohort who completed treatment with full dose, daily sofosbuvir-based regimens	Hector Enrique Nazario	Received

THU-220	Early regression of liver fibrosis evaluated by non-invasive methods after successful antiviral therapy in patients with HCV genotype 1b compensated cirrhosis	Anca Trifan	Received

SAT-220	Pre-emptive post-liver transplant hepatitis C virus treatment with daas: proof of concept from a pilot study	Luisa Pasulo	Received

SAT-221	High sustained viral response among hepatitis C virus genotype 3 patients with advanced liver fibrosis - real-world data of HCV elimination program in Georgia	Maia Butsashvili	Received

FRI-221	The „HCV Advisor" App - A web-based mobile application to identify suitable treatments with direct antiviral agents for chronic hepatitis C infection	Heiko Fruehauf	Received

FRI-222	Impact of directly acting antiviral drugs during treatment of decompensated cirrhosis with chronic hepatitis C	Vivek Anand Saraswat	Received

THU-222	The effect of ribavirin dosage on the kinetics of viral load decline and drug exposures in plasma and liver with OBV/PTV/r + DSV treatment in patients with chronic hepatitis C virus genotype 1a infection	Andrew H Talal	Received

FRI-223	New direct action antivirals containing regimes to treat patients with hepatitis C chronic infection: first results from a national real-world registry of the Brazilian Hepatology Society	Hugo Cheinquer H	Received

SAT-223	Impact of sustained virological response with DAAs in patients with compensated HCV cirrhosis and endoscopic esophageal varices study	Marc Puigvehí	Received

SAT-224	Hepatocellular carcinoma recurrence rate in HCV infected patients treated with direct antiviral agents. A single center experience	Marco Sanduzzi Zamparelli	Received

THU-224	Liver stiffness evaluated by means of ARFI is related not only to fibrosis in patients with hepatitis C virus-related chronic hepatitis	Annamaria Gesualdo	Received

FRI-224	Ribavirin free versus Ribavirin containing therapy with all second generation direct acting antivirals for the treatment of hepatitis C virus genotype 1 infection; a pooled analysis of 4501 patients	Hussien Ahmed	Received

THU-225	Four weeks of Ledipasvir/Sofosbuvir + Ribavirin with or without interferon gives very high and sustained cure rates in difficult to reach but easy to treat injecting drug users with chronic hepatitis C: final results of the 4WIDUC study	Anne Lindebo Holm Oevrehus	Received

FRI-225	Sustained Viral Response in patients who fail to complete hepatitis C treatment with Direct Acting Antivirals	Iain Hay	Received

FRI-226	Response guided addition of Sofosbuvir to pegylated interferon and ribavirin cures greater than 90% of patients with Genotype 3 infection and F0-2 disease	Iain Hay	Received

THU-226	Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy	Francesca Ceccherini-Silberstein	Received

SAT-226	Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice – preliminary data Vie-KinD study	Maria-Carlota Londoño	Received

THU-227	Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study	Antonio Massimo Ippolito	Received

THU-228	High sustained virological response rates in hepatitis C genotypes 1a and 4 patients treated with elbasvir and grazoprevir and basal viremia >800.000 UI/mL	Antonio Olveira	Received

FRI-228	Efficacy of oral Direct Acting Antivirals for the treatment of chronic hepatitis/cirhhosis due to hepatitis C virus infection: the real-life experience of the Sicily Registry	Irene Cacciola	Received

SAT-228	Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: The CHAMPS Study	Mark Sulkowski	Received

FRI-229	No adverse renal side effects in patients with mild to moderate renal dysfunction treated with Sofosbuvir	Iris Kuo	Received

FRI-230	The presence of two or more baseline NS5A resistance associated substitutions jeopardizes DAA treatment success in HCV patients	Itziar Carrasco Garcia	Received

SAT-230	Phase 1 study assessing the safety, pharmacokinetics, and antiviral activity of CC-31244, a pan-genotypic, potent non-nucleoside NS5B polymerase inhibitor for the treatment of hepatitis C virus infection	Mark Sulkowski	Received

THU-230	The effect of directly acting antivirals treatment on inflammatory status in HCV-infected patients, including those with recurrence of HCV-infection after liver transplantation: preliminary results of a prospective monocentric pilot study	Barbara Lattanzi	Received

SAT-231	Treatment of patients with hepatitis C virus genotype 5 and 6: descriptive analysis of the Hepa-C registry	Marta Hernández Conde	Received

SAT-232	Hepatitis C treatment with direct antiviral agents induce mild renal impairment	Marta Tejedor Bravo	Received

THU-232	The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments	Behzad Hajarizadeh	Received

FRI-232	Hepatitis C therapy delivered within and by a community addiction service: real life data shows SVR rates 90	Jacquelyn McGinley	Received

THU-233	Reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection in a community based setting	Beshoy Yanny	Received

SAT-233	High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: Integrated efficacy and safety analysis of genotype 1-6 patients without cirrhosis	Ed Gane	Received

SAT-234	Use of ledipasvir/sofosbuvir in patients with advanced chronic kidney disease (eGFR =30ml/min): a case series	Joseph Llewellyn	Received

THU-234	Grazoprevir-elbasvir based therapy is safe and effective in patients with chronic kidney disease GFR <30 and patients with end stage renal disease who are on renal replacement therapy in a community based setting	Beshoy Yanny	Received

FRI-234	Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study	Jason Grebely	Received

FRI-235	SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy	Jason Grebely	Received

THU-235	Direct acting antivirals improve neutrophil phagocytic capacity in chronic hepatitis C	Bettina Leber	Received

SAT-235	Plasma miR-122 levels in chronic hepatitis C patients achieving sustained virological response following DAA treatment with and without previous anti-miR-122 (RG-101) dosing	Meike H. van der Ree	Received

SAT-236	The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis	Michael Manns	Received

THU-236	Using all-oral hepatitis C virus therapy to reduce recurrent viremia and increase SVR	Arshia Alimohammadi	Received

FRI-237	HepCom: Impact of co-morbidities on the final success of direct antiviral agents therapy in hepatitis C	Javier Ampuero	Received

SAT-238	Drug-drug interactions of high prevalence in a real world hepatitis C treatment setting: the impact on treatment and the implications for patient management	Miriam Coghlan	Received

THU-238	Feasibility and acceptability of a group medical visit intervention to improve hepatitis C virus treatment uptake among persons who inject drugs (PWID) in a primary care setting	Brianna Norton	Received

FRI-238	Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection: an integrated analysis	Jean-Francois Dufour	Received

THU-239	Real-world use of elbasvir/grazoprevir and outcomes in patients with chronic hepatitis C: Retrospective data analyses from the TRIO Network	Bruce Bacon	Received

FRI-239	Analysis of the real-world treatment effectiveness of elbasvir/grazoprevir	Jeffrey Scott Mc Combs	Received

FRI-240	Obesity and high body weights predict ledipasvir/sofosbuvir treatment failure	David J. Witt	Received

THU-240	Outcome of patients with compensated liver cirrhosis with hepatitis B virus+hepatitis C virus coinfection treated with paritaprevir/ ombitasvir /ritonavir, dasabuvir with ribavirin: a national cohort study	Carmen Preda	Received

THU-241	Second generation direct acting antiviral agents improve clinical resource utilization required for hepatitis C eradication	Charles Mahoney	Received

FRI-241	Hepatitis C Care Continuum: Experience of an Emergency department screening programme	Jennifer Lee	Received

SAT-241	Outcomes of daclatasvir + sofosbuvir + riba in HEP C G3 patients who relapsed with SOF + RIBA combination therapy	Muzaffar Lateef Gill	Received

SAT-242	Comparison of vibration-controlled transient elastography (VCTE) with aspartate aminotransferase-to-platelet ratio Index (APRI) and platelet count for Identification of esophageal varices in patients with cirrhosis	Muzaffar Lateef Gill	Received

FRI-242	Changes in markers of liver function in hepatitis C virus genotype 1b Asian patients with compensated cirrhosis treated with ombitasvir/paritaprevir/ritonavir plus dasabuvir with ribavirin in the ONYX-II study	Jeong Heo	Received

THU-242	Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: a systematic review and meta-analysis	Cheng Wang	Received

THU-243	Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of hepatitis C virus -infected patients treated with recommended regimens	Chiara Masetti	Received

FRI-243	Cure of chronic hepatitis C patients receiving direct-acting antivirals correlated with partial restoration of HCV-specific T cell responses	Jijing Shi	Received

SAT-243	Prevalence and risk factors of hepatitis B virus reactivation in interferon-free direct-acting antiviral therapies for hepatitis C	Naoki Kawagishi	Received

FRI-244	Fibrosis regression in chronic hepatitis C patients after treatment with direct-acting antiviral agents is more effective than before – comparison of different noninvasive methods	Joana Rita Oliveira Alves Rita Carvalho	Received

THU-244	Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of hepatitis C virus infected patients with chronic kidney disease	Chiara Masetti	Received

SAT-244	Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network	Naoky Tsai	Received

SAT-245	Direct-acting antivirals for hepatitis C in patient in opioid substitution treatment and heroin assisted treatment: real-life data	Nathalie Scherz	Received

FRI-245	Total cholesterol and low-density lipoprotein increases after treatment with direct-acting antiviral agents – Implications in the future?	Joana Rita Oliveira Alves Santos Carvalho	Received

FRI-246	Successful implementation of HCV treatment in two large HIV clinics in Amsterdam: HCV treatment cascade of care	Job Saris	Received

SAT-246	Are DAAs reducing barriers for HIV co-infected and people who inject drugs? A population based cohort study	Naveed Janjua	Received

FRI-247	Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R)	Johannes Vermehren	Received

SAT-247	Assessment of glomerular filtration rate in hepatitis C virus patients after reaching sustained virologic response	Nelson Roberto Reyes Campos	Received

SAT-248	DAA-based regimens in HBsAg/anti-HCV positive patients: the need to control HBV replication to avoid HBV reactivation	Nicola Coppola	Received

FRI-248	Clinical and virological characteristics of patients with chronic hepatitis C virus (HVC) infection and failure to multiple direct acting antiviral (DAA) therapies	Johannes Vermehren	Received

THU-249	Efficacy and safety of sofosbuvir and daclatasvir for 8 weeks in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus genotype 3 infection	Christophe Hezode	Received

SAT-249	Real world experience of direct acting antiviral agents in hepatitis C virus genotype 4: encouraging outcomes from a UK-based cohort	Nina Stafford	Received

FRI-249	Efficacy and safety of Simeprevir-containing hepatitis C therapy in patients on opiate substitution therapy	John Dillon	Received

FRI-250	Very high real-world efficacy of ritonavir boosted paritaprevir with ombitasvir and dasabuvir +/- ribavirin in hepatitis C genotype 1 in patients with advanced fibrosis – final results of the REV1TAL study	John Samuel Lubel	Received

THU-250	Treatment of "acute" hepatitis C virus in human immunodeficiency virus-infected men with short-course sofosbuvir/ledipasvir	Daniel Seth Fierer	Received

FRI-252	Strong decrease of patients with advanced liver disease and more adherence problems to HCV therapy as DAA regimen enter third year of existence in Germany	Jörg Petersen	Received

SAT-252	Changes in the lipid profile in hepatitis C virus infected patients treated with direct-acting antivirals	Pedro Linares	Received

THU-253	Effects of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection on serotonin metabolism, depression scores and fatigue	Daphne Hahn	Received

FRI-253	Adherence to SmPC recommendations in real-world practice in the treatment of monoinfected patients with chronic genotype 1 or 4 HCV infection with direct-acting antivirals	José Luis Calleja Panero	Received

FRI-254	Effectiveness of ribavirin use associated with direct-acting antivirals in the treatment of non-cirrhotic patients with genotype 1a or 4 HCV infection in real-world practice	José Luis Calleja Panero	Received

THU-254	Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: results from clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin	Darshan Mehta	Received

THU-255	Treatment outcomes of hepatitis C virus recombinant form 2k/1b with sofosbuvir based regimens in Georgia	David Metreveli	Received

FRI-255	INTER-COLLaborative HEPatitis C: real-world treatment of hepatitis C patients by non-expert specialist providers in small and medium size Portuguese hospitals	Jose Ramos	Received

SAT-255	Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world	Philippe Halfon	Received

SAT-256	Molecular characterization of Hepatitis C virus resistance-associated substitutions after interferon-free treatment failure by massive parallel sequencing	Qian Chen	Received

FRI-256	Suitability of HCV treatment in primary care settings for individuals with HIV/hepatitis C coinfection	Joseph S Doyle	Received

THU-256	Hepatitis C: year 1 real life results from the All Wales hepatitis C roll out programme	David Samuel	Received

FRI-257	Short-term effect of DAA IFN-free regimens on liver stiffness	Juan A. Pineda	Received

SAT-257	Improved virological outcomes and excellent safety profile in genotype 3 HCV-infected cirrhotic patients after an extended 24-weeks course of daclatasvir, sofosbuvir + ribavirin: insights from a real-life multicenter study	Raffaella Lionetti	Received

SAT-258	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin (RBV) in hepatitis C virus genotype 1- infected patients with compensated cirrhosis and multiple comorbidities	Raluca Cezara Popa	Received

THU-258	12 weeks of sofosbuvir, daclatasvir and ribavirin for GT3 patients with cirrhosis	Debbie Troland	Received

FRI-258	Resistance patterns in patients with chronic hepatitis C genotype 4 infection and treatment outcome	Julia Dietz	Received

SAT-259	An exploratory study to evaluate immune restoration after removal of viral antigen in adults with genotype 1a chronic hepatitis C virus infection treated with ombitasvir/oparitaprevir/ritonavir + dasabuvir and ribavirin for 12 weeks	Jacinta A. Holmes	Received

FRI-259	High SVR 12 rates following treatment with direct acting antiviral agents (DAA) in a German multicentre cohort of HCV/HIV-1 coinfected patients on the transplant waiting list with advanced liver cirrhosis	Julia Schwarz	Received

THU-259	Retreatment of hepatitis C virus daa failures in real life: Easy and difficult to cure patients	Denis Ouzan	Received

FRI-260	Efficacy of therapy against chronic hepatitis C virus genotype 1 infection in HIV-coinfected patients with several interferon-free DAA combinations: Real life data from the HEPAVIR-DAA Cohort	Juan A Pineda	Received

SAT-260	Lipid modification in hepatitis C virus-monoinfected patients treated with direct acting antivirals	Regina Juanbeltz	Received

THU-260	Hepatitis C virus-RNA decay with direct acting antivirals in human immunodeficiency virus/hepatitis C virus coinfected patients	Diletta Barbanotti	Received

THU-261	Effect of interferon free antiviral therapy on glomerular and tubular kidney involvement in hepatitis C virus child-A cirrhosis	Donatella Palazzo	Received

SAT-261	Real world experience: Treating Hepatitis C in Alice Springs, Australia 2007-16	Robert Gordon Batey	Received

THU-262	Prospective study of autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct acting antivirals	Doroteo Acero Fernández	Received

FRI-262	CERTAIN-1: efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis	Fumitaka Suzuk	Received

SAT-262	Cirrhosis regression does not prevent hepatocellular carcinoma in patients with a sustained virological response to IFN	Roberta D´ambrosio	Received

SAT-263	Optimization of direct antiviral agent treatment schedule in hepatitis C virus genotype 3 infection: an Italian, multicentetric experience in real-life setting	Filomena Morisco	Received

FRI-263	Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection with and without cirrhosis	Tsunamasa Watanabe	Received

THU-263	Pharmacokinetics and safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection and compensated cirrhosis: an integrated analysis	Edward Gane	Received

SAT-264	Sustained virological response in HCV patients treated with daclatasvirsofosbuvir, with or without ribavirin: a multicenter, field-practice experience	Rodolfo Sacco	Received

SAT-265	DAAs increase serum VEGF level: a rationale for tumour risk recurrence during anti-HCV treatment	Rosanna Villani	Received

FRI-265	Benefit of direct-acting antiviral therapy in hepatitis C virus (HCV) monoinfected and HIV-HCV coinfected patients with mixed cryoglobulinemia	Kerstin Hartig-Lavie	Received

SAT-266	Excellent efficacy but increased rate of severe adverse events in HCV-infected elderly patients undergoing interferon-free therapy	Sabela Lens	Received

THU-267	Effectiveness and safety of sofosbuvir-based regimens for Japanese patients with hepatitis C virus genotype 1b or 2 infection: real life experience from a multicenter cohort	Eiichi Ogawa	Received

THU-268	High efficacy of 8 weeks of ledipasvir/sofosbuvir in real-world treatment	Eleanor Wilson	Received

SAT-268	Effect of hepatitis C treatment with ombitasvir/paritaprevir/ritonavir+dasabuvir regimen on patient`s health related quality of life: Analysis of Phase 3a and phase 3b clinical trials	Darshan Mehta	Received

THU-269	Changes in renal function in patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents	Eleni Theocharidou	Received

SAT-269	Drop-out rate due to HCC progression is not affected by HCV eradication with DAAs in patients awaiting liver transplantation	Sarah Shalaby	Received

FRI-270	Antiviral therapy in patients with chronic hepatitis C related hepatocellular carcinoma responding to palliative treatment	Kwan Sik Lee	Received

THU-270	Management of drug-interactions with DAAs in Dutch human immunodeficiency virus/hepatitis C virus co-infected patients: adequate but not perfect	Elise Joëlle Smolders	Received

SAT-270	Results of hepatitis C treatment program among people who inject drugs	Sergii Filippovych	Received

FRI-271	Comparison of efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin between Asian and western HCV GT1b-infected patients	Lai Wei	Received

THU-271	Improvement of glycemic state among responders to sofosbuvir – based DAAs	Shereen Abdel Alem	Received

SAT-271	On-treatment HCV RNA monitoring is not a cost-effective means of identifying non-adherence and has no predictive value	Shirin Demma	Received

FRI-272	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in Asian patients with genotype 1b chronic hepatitis C virus infection and compensated cirrhosis: ONYX-II post-treatment week 24 results	Lai Wei	Received

SAT-272	Characterization of novel GT-1b resistant-associated substitutions (RASs) selected by NS5A inhibitor-based regimens	Slim Fourati	Received

THU-272	Prevalence of serum non organ specific antibodies in patients with chronic hepatitis c and their influence in direct-acting antivirals therapy	Endrit Shahini	Received

SAT-273	Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1 6 and chronic kidney disease: an integrated analysis	Stan Pol	Received

FRI-273	Efficacy and safety of Ombitasvir/paritaprevir/ritonavir and dasabuvir in non-cirrhotic Asian patients with genotype 1b chronic hepatitis C virus infection: ONYX-I post-treatment week 24 results	Wan-Long Chuang	Received

FRI-274	Efficacy and safety of Direct-Acting Antiviral Drugs in patients with thalassemia major and crhonic hepatitis C: a preliminary report of a single italian center	Laura Ponti	Received

THU-274	Lack of clinical benefit of direct acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis	Estefania Berge	Received

THU-275	High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry	Ester Badia Aranda	Received

FRI-275	No increased risk of hepatocellular carcinoma recurrence in patients following interferon-free, direct acting anti-viral treatment for hepatitis C virus: a cohort study using large-scale administrative medical claims data	Anand P. Chokkalingam	Received

FRI-276	In vitro virology profile of the 3 direct-acting antiviral combination of AL-335, odalasvir and simeprevir	Leen Vijgen	Received

THU-276	Evolution of platelets in chronic hepatitis C infected patients and advanced liver fibrosis after direct-acting antiviral treatment	Ester Badia Aranda	Received

SAT-276	Effect of eradicating hepatitis c on alanine aminotransferase levels	Stefan Mauss	Received

SAT-277	Worsening of serum lipid profile after direct acting antiviral treatment	Stefano Gitto	Received

FRI-277	Directly active antivirals pharmacokinetics in HCV/HIV co-infected patients with advanced hepatic fibrosis	Letizia Marinaro	Received

FRI-278	Decrease of Interleukin-6 and Interleukin-8 blood levels after successful interferon-free anti-HCV treatment	Lorenzo Badia	Received

SAT-278	Directly observed therapy with sofosbuvir/ledipasvir for 8 weeks is highly effective in treatment-naïve, precirrhotic genotype 1 patients with borderline compliance receiving opioid agonist therapy	Stephan Moser	Received

THU-278	The eradicate-C study-curing people who are actively injecting drugs of hepatitis C: the first step to elimination	Farsana Ahmad	Received

SAT-279	Real-world treatment utilization and results in the renaissance of HCV Care: Analyses of treatment for 7,550 Patients from the TRIO Network	Steven Flamm	Received

FRI-279	Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort	Loreta A Kondili	Received

THU-279	Comorbidities and metabolic disorders associated to hepatitis C virus infection: their implications in the severity of the disease and overall mortality risk	Fátima Serejo	Received

FRI-280	Clinical characterization and economic impact evaluation of anti- HCV DAA treatment failure: real life data from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER)	Loreta A. Kondili	Received

THU-280	Real life retreatment of patients failing DAAs in Spain: data from the HCVREsp cohort	Federico García	Received

FRI-281	Relapse after direct-acting antivirals (DAAs) in cirrhotic patients with hepatitis C is highly related to development of liver cancer	Luisa Cavalletto	Received

THU-281	Low rate of drug-drug interaction management during interferon-free simeprevir therapy - An integrated analysis of interventional and observational clinical studies	Fiona Marra	Received

FRI-282	Genotype 3 infection in DAA era: reports of a real life NORTHERN ITALY NETWORK FOR VIRAL HEPATITIS after 2 years by the start	Luisa Pasulo	Received

SAT-282	The macrophage activation marker, soluble CD163 is associated with hepatic inflammation and fibrosis in chronic viral hepatitis C and declines during effective direct-acting antiviral therapy	Tea Lund Laursen	Received

THU-282	Successful management of drug interactions with ritonavir-containing hepatitis C virus regimens in routine clinical practice	Fiona Marra	Received

THU-283	Changes in liver stiffness assessment in chronic hepatitis c patients treated with direct-acting antivirals: monocentric experience between 2015 and 2016	Elke Maria Erne	Received

SAT-283	Real-world effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection within national hepatitis C elimination program in the country of Georgia	Tengiz Tsertsvadze	Received

FRI-283	The old patient in DAA era: real life reports on 5925 patients from the Lombardy HCV Network	Luisa Pasulo	Received

FRI-284	Virus-specific coexpression of T-bet and Eomes defines highly functional CD8 and CD4 T cells in hepatitis B virus infection	Hadi Karimzadeh	Received

SAT-284	Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia	Tengiz Tsertsvadze	Received

THU-284	Cost-effectiveness of elbasvir-grazoprevir association for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France	Franck Maunoury	Received

FRI-285	Hepatitis E virus-specific T cell responses against non-structural viral proteins in patients with ongoing and resolved hepatitis E	Jana Al-Ayoubi	Received

THU-285	Efficacy and safety of the fixed-dose combination regimen of MK3 MK-3682/grazoprevir/ruzasvir with or without ribavirin in non-cirrhotic or cirrhotic patients with chronic HCV GT1, 2, 3, 4 or 6 infection (Parts A & B of C-CREST-1 & 2)	Frank Dutko	Received

FRI-286	The impact of ERAP1 polymorphisms on virus-specific CD8+ T cell responses in an HLA*B27+ patient with acute hepatitis C virus infection	Janine Kemming*	Received

SAT-286	Outcome of liver transplantation in HCV infected patients – implications for antiviral treatment decisions	Thomas Kuntzen	Received

THU-286	Chronic hepatitis C in children in the Russian Federation: a multicenter study	Tamara Skvortsova	Received

SAT-287	Virological and clinical significance of detectable HCV-RNA below limit of quantification at End-of-Treatment in patients treated with direct antiviral agents	Ubaldo Visco Comandini	Received

SAT-288	The challenge of HCV-retreatment after DAA-failure: real-life experience advocates for caution	Valeria Cento	Received

THU-288	Neutralizing activity of non-polyreactive monoclonal antibodies directed against the hepatitis C virus E2 glycoprotein isolated from patients with spontaneous resolution	Anne Olbrich	Received

THU-289	Infectious hepatitis C virus particle assembly is inhibited by paritaprevir and ombitasvir	David R Mcgivern	Received

SAT-289	Interferon-free direct-acting antiviral therapy decreases the rate of hepatocellular carcinoma recurrence in patients with chronic hepatitis C and advanced fibrosis	Victor Virlogeux	Received

FRI-290	Pegylated interferon alpha treatment rapidly clears hepatitis E virus infections in humanized mice	Thomas Vanwolleghem	Received

THU-290	Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals	Elena Perpiñán Mas	Received

SAT-290	Liver decompensation predicts ribavirin overexposure in HCV cirrhotic patients treated with direct-acting antiviral agents	Viola Guardigni	Received

FRI-291	KLRG1 impairs antiviral immunity of NK-cell in Individuals with Chronic Hepatitis B Virus Infection via the Akt pathway	Ming-Hong Li	Received

SAT-291	Impact of hepatoprotective medications on the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in hepatitis C virus genotype 1b-infected Asian patients with and without cirrhosis in the ONYX-I and -II studies	Wan-Long Chuang	Received

SAT-292	Liver function as measured by albumin-bilirubin score within decompensated patients receiving direct acting antiviral therapy within the Expanded Access Programme	Philip Johnson	Received

FRI-292	B-Cell depletion therapy with rituximab in patients with hepatitis C virus mixed cryoglobulinemic vasculitis improves B- and T-Cell phenotype and function	Poonam Mathur	Received

THU-292	Molecular mechanisms of fitness compensation in drug resistance-associated NS3 protease variants in hepatitis C	Georg Dultz	Received

FRI-293	Mucosal-associated invariant T lymphocytes are declined, activated, and exhausted in peripheral in chronic HBV-infected patients	Qian Liu	Received

SAT-293	Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C after living donor liver transplantation: a Japanese multicenter experience	Yoshihide Ueda	Received

FRI-294	Metabolic properties of epigenetically regulated adaptive versus conventional NK cells are conserved in chronic viral hepatitis	Anita Schuch	Received

SAT-294	Early versus delayed hepatitis C treatment provides increased health benefits at lower costs: A UK cost-effectiveness analysis of genotypes 1 and 4 treatment-naïve patients	Yuri Sanchez Gonzalez	Received

THU-294	Allelic variantes of Aurora B kinase gene can be related with fibrosis progression in chronic hepatitis C	Irene Francisco-Recuero	Received

SAT-295	A budget optimization analysis for the treatment and potential elimination of hepatitis C virus infection in the United States	Yuri Sanchez Gonzalez	Received

FRI-295	CCR5 T cells are primary responders to HCV subject to exhaustion and contribute to ongoing hepatic inflammation	Shikha Shrivastava	Received

FRI-296	Myeloid-derived suppressor cells: key players mediating immunosuppression via induction of regulatory T-cell by TGF-ß and IL-10 driven pathways in chronic HBV infection	Sourina Pal	Received

SAT-296	Direct acting antivirals did not increase early recurrences after curative treatment of HCV related hepatocellular carcinoma in comparison with IFN-based treatment	Yutaka Yasui	Received

THU-296	Hepatocyte single cell sequencing to identify transcript modulation by hepatitis C virus	Jose Daniel Debes	Received

THU-297	Multiple ascending dose study of seraprevir potassium, a nonstructural protein 3/4A replication complex inhibitor, in patients infected with hepatitis C virus	junqi niu	Received

SAT-297	Elbasvir/Grazoprevir effectiveness in patients with chronic hepatitis C and chronic kidney disease: real-world experience from the TRIO Network	Zobair Younossi	Received

FRI-297	Transcriptome profiles of NK and T cells associated with immune control in chronic hepatitis B patients treated with pegylated interferon alpha-nucleos(t)ide analogue sequential therapy	Upkar S. Gill	Received

FRI-298	Human leukocyte antigen and IL28B polymorphisms independently associated with hepatitis C virus RNA spontaneous clearance: a study from REVEAL-HCV cohort	Yu-Han Huang	Received

THU-298	Inosine triphosphate pyrophosphatase enhances the effect of ribavirin on hepatitis C virus cell culture infection	Kristina Nyström	Received

SAT-298	HEV as a cause of acute hepatitis acquired in Switzerland	Montserrat Fraga Christinet	Received

THU-299	Identification of glycogen synthase kinase 3 beta as a novel host factor of hepatitis C virus replication	Maged Saleh	Received

SAT-299	Solithromycin treatment for 13 weeks improves histological parameters in nonalcoholic steatohepatitis: results of an ongoing pilot study	Pierre Gholam	Received

SAT-300	The severity of steatosis does not influence liver stiffness measurements in patients with non-alcoholic fatty liver disease	Roberta Forlano	Received

THU-300	Viral load at 15 days after liver transplantation as a good predictor of fast liver fibrosis progression	Meritxell Llorens	Received

FRI-300	Disease spectrum of alcoholic liver disease in beijing 302 hospital from 2002-2013: a large tertiary referral hospital experience from 7422 patients	Ang Huang	Received

SAT-301	Prevalence of combined PNPLA3 and GCKR variant genotype is increased in patients with risk factors for alcoholic or non-alcoholic liver disease who have clinically significant serum pro-collagen III levels	Prarthana Thiagarajan	Received

THU-301	In vitro inhibition of hepatitis C virus with ribavirin is strain dependent and leads to RNA mutagenesis	Niels Mejer	Received

FRI-301	MAIT cell dysfunctions correlate with markers of intestinal integrity in ALD patients	Antonio Riva	Received

FRI-302	Variation in the use of corticosteroids for the treatment of acute severe alcoholic hepatitis in the post-STOPAH era: results of a UK national survey	Ashwin Dhanda	Received

SAT-302	Prevalence of nonalcoholic fatty liver disease in lean adolescents in the United States: an analysis of national health and nutrition examination survey data	Naim Alkhouri	Received

THU-302	MIV-802, a uridine nucleotide prodrug, is a more potent inhibitor of hepatitis C virus genotype 3 replication than sofosbuvir	Richard Bethell	Received

THU-303	Systematic review & expert guidance on methods for sequencing of hepatitis C virus for detection of direct-acting antiviral resistance	Sofia R Bartlett	Received

SAT-303	Prevalence and risk factors of nonalcoholic fatty liver disease in metabolically healthy obese adolescents in the United States: an analysis of national health and nutrition examination survey data	Naim Alkhouri	Received

FRI-303	Intermediate (CD14++CD16+) monocytes from patients with acute severe alcoholic hepatitis are activated and functionally similar to classical (CD14++CD16-) monocytes	Ashwin Dhanda	Received

FRI-304	No consensus among nutritional assessment tools for identification of malnutrition in patients with alcoholic liver disease	Chetan Ramesh Kalal	Received

SAT-304	Can modest alcohol intake be dismissed as a co-factor in diabetic patients with non-alcoholic fatty liver disease?	Preya Janubhai Patel	Received

FRI-305	Ethanol-induced depletion of Akkermansia muciniphila drives alcoholic liver disease	Christoph Grander	Received

THU-305	Resistance selection using glecaprevir and pibrentasvir in replicons of major hepatitis C virus genotypes	Teresa Ng	Received

SAT-305	Relationship between fatty liver, coronary calcium score, multiple-sites atherosclerosis and 10-years Framingham Score	Raluca Pais	Received

THU-306	Transcriptional response to hepatitis C virus infection in the human liver	Tuyana Boldanova	Received

SAT-306	Ethnicity and outcomes in non alcoholic fatty liver disease: prospective evaluation of 1500 cases	Richard Parker	Received

SAT-307	Development and validation of an automated system for assessment of liver steatosis and fibrosis in routine histological images in patients with non-alcoholic fatty liver disease	Roberta Forlano	Received

FRI-307	Effect of alcohol on the IL-6 mediated inflammatory response in a new mouse model of acute-on-chronic liver injury	Ersin Karatayli	Received

THU-307	Exosomal miRNAs derived from umbilical mesenchymal stem cells inhibit hepatitis C virus infection	Zhongtian Qi	Received

THU-308	Direct antiviral agents therapy can induce a partial restoration of the antiviral immune functions in patients with chronic hepatitis C virus infection	Amalia Penna	Received

FRI-308	A two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption	Flaminia Ferri	Received

FRI-309	Differential gender-related impact of PNPLA3 and CD14 polymorphism on the risk of developing alcoholic cirrhosis	Flaminia Ferri	Received

THU-309	Role of SerpinB3 in the stimulation of macrophage activation marker sCD163 in hepatitis C virus infected patients	Andrea Martini	Received

SAT-309	Obesity and steatosis severity affect diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease	Yong Jin Jung	Received

THU-310	Preferential recognition of hepatitis B virus-DNA integrated target by hepatitis B virus-specific CD8 T cells	Atefeh Khakpoor	Received

FRI-310	Hair ethyl glucuronide is a highly accurate and objective biomarker of continued alcohol use in patients with alcoholic cirrhosis	Frederik Nevens	Received

SAT-310	Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with nonalcoholic fatty liver disease	Salvatore Petta	Received

SAT-311	Emerging Increase in the prevalence and severity of nonalcoholic fatty liver disease: epidemiological study from general Mediterranean population	Salvatore Petta	Received

THU-311	Impaired T follicular helper cell-B cell axis in chronic HBV infection despite long-term antiviral treatment	Bhawna Poonia	Received

FRI-311	The effect of nurse performed telemedical video consultations for patients suffering from alcohol-related liver cirrhosis	Ghita Bellis Thygesen	Received

THU-312	MAIT cell frequency and function in blood and liver of hepatitis C virus mono- and hepatitis C virus/human immunodeficiency virus co-infected patients with mild versus advanced fibrosis	Boris Beudeker	Received

SAT-312	A randomized, double-blind, placebo-controlled study to evaluate the efficacy of a multispecies probiotic mixture in obese non-alcoholic fatty liver disease	Sang Bong Ahn	Received

FRI-312	Carcinogenic Etheno DNA-adducts in alcohol liver disease: correlation with cytochrome P-4502E1 and fibrosis	Helmut Karl Seitz	Received

SAT-313	Dynamic FDG-PET study of liver inflammation in non-alcoholic fatty liver disease	Souvik Sarkar	Received

THU-313	Identification of a highly cross-reactive CD8+ T cell repertoire that recognizes a hepatitis E virus peptide and an apoptotic epitope	Chai Fen Soon	Received

FRI-313	Iron promotes ADAM-17 mediated sCD163: TNF-a liberation and modulates inflammation in severe alcoholic hepatitis	Jaswinder Singh Maras	Received

THU-314	Macrophage-derived extracellular vesicles mediate a long-lasting innate immune response against hepatitis C virus	Chengcong Cai	Received

FRI-314	Physiologic Staging in alcoholic Liver Disease Predicts Death and Monitors Recovery	John Carl Hoefs	Received

SAT-315	Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies	Stuart Mcpherson	Received

THU-315	Hepatitis B virus affects dendritic cell activation and their crosstalk with natural killer cells	Claudia De Pasquale	Received

FRI-315	Effects of probiotics (Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052) in the treatment of mild alcoholic hepatitis: randomized controlled multicenter study	Ki Tae Suk	Received

SAT-316	Paired biopsy analysis of human liver transcriptome before and 1 year after bariatric surgery identifies a restricted set of inflammation- and extracellular matrix-related genes as pivotal in NASH and fibrosis pathogenesis	Sven Marcel Francque	Received

THU-317	N22 region based dot blot assay: an alternative to PCR for detection of Torque teno virus infection	Dhananjay Singh Mankotia	Received

FRI-317	Autologous hematopoietic stem cell transplantation into the liver: impact on hepatic macrophagic expansion and gene expression	Nicolas Lanthier	Received

SAT-317	Association of A313G polymorphism of GSTP1 gene with certain biochemical markers of liver injury, pro- and anti-inflammatory cytokines in patients with nonalcoholic fatty liver disease	Vasyl Prysyazhnyuk	Received

THU-318	NS3 inhibition coupled with potent direct acting antiviral combinations leads to enhanced hepatitis C virus specific immunity in hepatitis C virus-human immunodeficiency virus co-infected patients	Eleanor McKenna Pitt Wilson	Received

THU-319	Toll-like receptor 5 polymorphism at position c.1846T>C is associated with the development of hepatocellular carcinoma in caucasians with chronic hepatitis B infection	Janett Fischer	Received

FRI-319	Long-term disease progression in chronic hepatitis B Chinese patients with comorbid nonalcoholic fatty liver disease	Jian Gao Fan	Received

SAT-319	Non-alcoholic fatty liver disease – demographic features, risk factors and treatment practices across the Asia Pacific region – the GO ASIA initiative	Wah Kheong Chan	Received

FRI-320	Taste and appetite disorders in patients with non-alcoholic fatty liver disease	Joanna Musialik	Received

SAT-320	Blood-test based assessment of liver fibrosis, but not transient elastography, is less accurate in NAFLD patients of South Asian compared to White ethnicity	William Alazawi	Received

SAT-321	Periodontitis is strongly associated with NAFLD in the NHANES III cohort and in an independent prospective study, is more common in those with biopsy-proven advanced compared to mild liver disease	William Alazawi	Received

THU-321	TRAF1 as a marker of exhaustion during chronic hepatitis C	Elia Moreno	Received

FRI-321	Steatohepatitis: differential features on quantitative liver-spleen scan	John Carl Hoefs	Received

FRI-322	Vitamin D serum levels are only marginally lower in hepatic steatosis and do not correlate with Vitamin D dietary ingestion	Jorge Leitão	Received

SAT-322	Safety and pharmacokinetics of DUR-928 in patients with nonalcoholic steatohepatitis– a phase 1b study	William Kemp	Received

SAT-323	Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment	William Malcolm Rosenberg	Received

FRI-323	Hepatic steatosis in an adult population: stronger correlation with the presence of obesity and insulin resistance than with the dietary pattern. Results from a cross-sectional study	Jorge Leitão	Received

FRI-324	Evaluation of a novel nurse-led one-stop clinic for patients referred for investigation of suspected non-alcoholic fatty liver disease	Kirsty Fancey	Received

SAT-324	Comparison of risk factors for nonalcoholic steatohepatitis and advanced fibrosis between patients with obese and non-obese nonalcoholic fatty liver disease	Won Kim	Received

THU-324	No change in hepatitis C virus-specific T cell functionality after successful DAA treatment in chronic hepatitis C patients	Femke Stelma	Received

THU-325	Ki67, cyclin D and caspase 3 allow distinction of two sub-groups of alcoholic patients at early stages of alcoholic liver disease	Peter Stärkel	Received

SAT-325	Assessment of the hepatic steatosis using controlled attenuation parameter (CAP) measured with transient elastography in healthy population	Young Mi Hong	Received

FRI-325	High liver iron in biopsy of NAFLD patients is a predictor for cardiovascular and liver-related mortality	Elmar Aigner	Received

FRI-326	The COMMANDS study: improving community-based diagnosis and management of non-alcoholic fatty liver disease	Laura Burke	Received

SAT-326	Health-related quality of life in patients with non-alcoholic fatty liver disease	Yvonne Huber	Received

SAT-327	Non-alcoholic steatofibrosis is independently associated with both overall mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)	Zobair M Younossi	Received

FRI-327	Effective dietary interventions for non-alcoholic fatty liver disease: barriers and facilitators to adoption of a Mediterranean diet in a northern European patient population	Laura Haigh	Received

THU-327	Development of a novel murine model of acute alcoholic hepatitis	Richard Wilkin	Received

FRI-328	Presarcopenia is associated with non-alcoholic fatty liver disease (NAFLD) in older women: The Rotterdam Study	Louise Johanna Maria Alferink	Received

SAT-328	Can atherosclerotic cardiovascular risk score (ASCVD) predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)?	Zobair M Younossi	Received

THU-328	Evaluation of potential futility in alcoholic hepatitis – multicentre study	Rita Barosa	Received

SAT-329	Down-regulation of hepatic MBOAT7 by hyperinsulinemia favors steatosis development	Marica Meroni	Received

FRI-329	Severe histological liver phenotype of lean subjects with non-alcoholic fatty liver disease	Lukas Denkmayr	Received

THU-329	Clinical criteria are of limited value for diagnosis of alcoholic steatohepatitis	Rudolf E. Stauber	Received

THU-330	Drinking behaviour and rs738409:G in PNPLA3 are associated with slower recovery of liver function following severe alcoholic hepatitis	Stephen R Atkinson	Received

FRI-330	NAFLD as an indication for liver transplantation in the Nordic countries – a cohort study during 1982-2015	Magnus Holmer	Received

SAT-331	Comparative effects of liraglutide, elafibranor and obeticholic acid on NAFLD activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed NASH	Michael Feigh	Received

THU-331	Low serum transferrin indicates short-term mortality in severe alcoholic hepatitis	Stephen Atkinson	Received

FRI-331	Effects of gene variants controlling vitamin D metabolism and serum levels on hepatic steatosis	Malgorzata Jamka	Received

THU-332	Serum procalcitonin correlates with baseline renal function and predicts mortality in severe alcoholic hepatitis	Stephen R Atkinson	Received

SAT-332	Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice	Mitchell Bijnen	Received

FRI-333	Exploring the patient perceived impact of non-alcoholic steatohepatitis	Maria-Magdalena Balp	Received

FRI-334	How often do we misclassify alcoholic as nonalcoholic fatty liver disease due the subjectivity in assessing alcohol consumption?	Mariana Verdelho Machado	Received

SAT-334	Ingestion of wheat amylase trypsin inhibitors promotes a proinflammatory liver and adipose tissue phenotype in diet induced non-alcoholic fatty liver disease in mice	Muhammad Ashfaq-Khan	Received

THU-334	Alcoholic hepatitis histological scores predict short-term survival in Asian patients with biopsy-proven alcoholic hepatitis	Won Kim	Received

FRI-335	Nonalcoholic fatty liver with hepatic arterial buffer response strongly caused metabolic diseases, while bright pancreas was not associated with metabolic diseases - 5 years´ cohort	Masashi Hirooka	Received

THU-335	Investigating immunomodulatory roles of CX3CR1 related with differentiation and functional polarization of kupffer cells	Young-Sun Lee	Received

SAT-336	Clinical course and outcome of pregnancy in women with non alcoholic fatty liver disease	Nasser Mousa	Received

THU-336	The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study	Ahmet Uygun	Received

FRI-336	Liver steatosis and fibrosis in at-risk European HIV-monoinfected patients	Maud Lemoine	Received

FRI-337	Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients	Maud Lemoine	Received

SAT-337	Neurobehavioral disturbances and hyperammonemia are evident in rodent model of NAFLD prior to cirrhosis stages	Natalia Arias	Received

FRI-338	Serologically assessed extracellular matrix remodeling is affected by bariatric surgery in morbidly obese NAFLD patients with 12 months follow-up	Mette Juul Nielsen	Received

THU-338	Trends in hospital charges and encounters for patients with nonalcoholic fatty liver disease compared to patients with alcohol related liver disease in the United States between 2005 and 2013	Alexander Le Nguyen	Received

SAT-339	The effect of elafibranor and obeticholic acid on NAFLD Activity score and fibrosis stage in a novel metabolic rat model of diet-induced and biopsy-confirmed NASH	Niels Vrang	Received

FRI-339	First-in-Human study of LMB763, a novel, orally-available farnesoid X receptor agonist that demonstrates modulation of the pharmacodynamic markers FGF19 and C4 in healthy subjects	Bryan Laffitte	Received

THU-339	Liver-related mortality and morbidity of lean NAFLD is higher compared to overweight and obese NAFLD patients	Alexandra Feldman	Received

SAT-340	Precision-cut liver slices as an ex-vivo model for human NAFLD show hepatic progenitor cell activation and fibrogenesis	Olivier Govaere	Received

FRI-340	SAF score effectively identifies NAFLD subjects at high risk of subsequent liverrelated but not cardiovascular or malignancy-associated mortality and morbidity	Michael Strasser	Received

THU-340	Use of non-invasive methods to assess hepatic steatosis and advanced fibrosis in type-1 diabetic patients	Amandeep Singh	Received

THU-341	Prevalence of non–alcoholic fatty liver disease and advanced fibrosis in type - 2 diabetic patients via non-invasive methods	Naim Alkhouri	Received

FRI-341	An open-label randomized clinical study to compare the effects of a nutritional supplement versus vitamin E on fibroscan score in nonalcoholic steatohepatitis patients	Mohammad Shahed Ashraf	Received

SAT-341	miR-21 ablation and obeticholic acid ameliorate NASH in mice	Marta Bento Afonso	Received

SAT-342	Hepatic overexpression of chemerin attenuates expression of inflammatory and profibrotic genes in murine non-alcoholic steatohepatitis	Rebekka Pohl	Received

THU-342	Validation of non-invasive fibrosis assessments in biopsy-proven non-alcoholic fatty liver disease	Andreas Drolz	Received

FRI-342	The diagnostic accuracy of vibration controlled transient elastography for cirrhosis in subjects with nonalcoholic fatty liver disease	Mohammad Shadab Siddiqui	Received

FRI-343	Effect of a probiotic on fatty liver index and liver stiffness in NAFLD patients: randomized clinical trial	Natalia Bosak	Received

FRI-344	Changing eating behavior by motivational and controlled program during 12 weeks reduce weight, cytokeratin 18 levels and steatosis in patient with NAFLD	Nataliia Dynnyk	Received

THU-345	Individuation of presence and combination of genetic risk factors may help to refine the risk for most severe forms of NAFLD	Chiara Dell´Unto	Received

FRI-345	Influence of non-alcoholic fatty liver diease on the course of stable coronary heart disease	Iryna Igorivna Vakalyuk	Received

FRI-346	Role of a-ketoglutarate and ß-hydroxybutyrate in morbid obesity-associated non-alcoholic fatty liver disease: metabolomic approach	Noemí Cabré	Received

SAT-346	Prolonged-release pirfenidone is a dual activator for PPARalpha and PPARgamma and improves NASH features induced by high fat/carbohydrate diet	Roberto Rodriguez-Echevarria	Received

SAT-347	Steatogenic compounds induce triglyceride accumulation by multiple mechanisms in hepatocyte-like cells generated from human skin-derived precursors	Robim M Rodrigues	Received

FRI-347	PNPLA3, TM6SF2 and MBOAT7 genotypes and coronary artery disease	Nynke Simons	Received

THU-347	A new French paradox: morbidly obese patients with NASH have less bulimia than those without NASH	Clemence M Canivet	Received

SAT-348	The severity of portal inflammation is associated with hepatic fibrosis stage and components of metabolic syndrome in NAFLD	Sae Kyung Joo	Received

THU-348	Simple sugar consumption associated abnormal aminotransferase activity without intrahepatic fat: A cross sectional observational study	Dae Won Jun	Received

THU-349	Autonomic function is impaired across the spectrum of NAFLD	David Houghton	Received

THU-350	Cardiovascular risk factors are independent of fibrosis severity in NAFLD	Davide Roccarina	Received

FRI-350	Sprint interval exercise training reduces intrahepatic, visceral and subcutaneous abdominal fat despite no change in body weight, but has variable effects on whole-body insulin sensitivity	Jack Alistair Sargeant	Received

FRI-351	Hepatocyte nuclear factor 4a played a different role in lipotoxicity and bile acid toxicity in non-alcoholic fatty liver disease model	Jai Sun Lee	Received

SAT-351	Hepatotropic effects of granulocyte colony stimulating factor in non-alcoholic fatty liver disease: beyond marrow cell mobilization	Sang Bong Ahn	Received

THU-351	Estimation of serum "true collagen type III formation" (Pro-C3) levels as a marker of non-alcoholic steatohepatitis in a prospective cohort	Diana Julie Leeming	Received

THU-352	Nonalcoholic fatty liver disease and development of chronic kidney disease: a retrospective cohort study	Dong Hyun Sinn	Received

SAT-352	Role of group 2 innate lymphoid cells in the prevention of high-fat diet-induced nonalcoholic steatohepatitis by caffeine	Shuhei Hayashi	Received

THU-353	Metabolic and biochemical phenotypes can distinguish different patterns of histological severity in biopsy-proven NAFLD	Eduardo Vilar Gómez	Received

FRI-353	Serum cholesterol changes associated with NGM282 treatment in obese insulin resistant cynomolgus monkeys are reversed with either a statin or a PCSK9 inhibitor	Jian Luo	Received

SAT-353	Genetic polymorphism of PTPRD (rs35929428) and risk of non-alcoholic fatty liver disease in Japanese	Shunsuke Nakajima	Received

THU-354	Performance of the fibroscan and other noninvasive scales for detecting hepatic fibrosis in patients with nonalcoholic fatty liver disease	Esteban Saez	Received

SAT-354	Therapeutic effect of cerium oxide nanoparticles (CeO2NPs) in rats with diet-induced non-alcoholic steatohepatitis	Silvia Carvajal	Received

FRI-354	Elevated hepatic and adipose hepcidin expression in patients with advanced NAFLD fibrosis	John Denis Ryan	Received

SAT-355	Annexin A1 supplementation prevents the progression to fibrosis of nonalcoholic steatoepatitis (NASH)	Stefania Bruzzì	Received

THU-355	The role of dysbiosis in the development of non-alcoholic fatty liver disease in obese patients	Esther Nistal	Received

THU-357	Low vitamin D level is not associated with severity of non-alcoholic fatty liver disease in morbidly obese patients	Ana de Lourdes Candolo Martinelli	Received

FRI-357	Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mouse	Joost Willebrords	Received

SAT-357	Inhibition of IL6 trans-signaling leads to gut microbiota-dependant mature-onset obesity and metabolic syndrome	Eithan Galun	Received

FRI-358	Aramchol reduces established fibrosis in MCD diet animal model	José M Mato	Received

SAT-358	Adipose type I interferon signalling protects against metabolic dysfunction	Timon Adolph	Received

THU-358	Fasting serum bile acids profile and insulin resistance in healthy blood donors	Francesco Azzaroli	Received

SAT-359	CD103+ DCs are a key population in the progression of non-alcoholic steatohepatitis: could DCs represent a novel therapeutic application in NASH?	Veronika Lukacs-Kornek	Received

THU-359	Non-alcoholic fatty liver disease, hyperglycemia and overweight in the elderly: simple traveling companions or criminal conspiracy?	Giampaolo Bianchi	Received

FRI-359	New GLP-1 agonist dulaglutide improves metabolic dysfunction and extenuates development of non-acoholic steatohepatitis in mice	Katharina Luise Hupa	Received

FRI-360	Bone morphogenetic protein (BMP)-9 enhances high glucose-mediated vascular damage	Katja Breitkopf-Heinlein	Received

THU-360	Presence of metabolic syndrome and low CD4 count are independently associated with liver fibrosis in human immunodeficiency virus-infected patients with non-alcoholic fatty liver	Hugo Perazzo	Received

SAT-360	Altered methylation of FADS2 in NASH is partly explained by FADS2 genotypes	Jussi Pihlajamäki	Received

SAT-361	Receptor-interacting protein kinase 3 acts differently according to non-alcoholic fatty liver disease model	Waqar Khalid Saeed	Received

THU-361	Long term clinical implication of nonobese non-alcoholic fatty liver disease: comparison with metabolically abnormal but normal weight	Jae Youn Cheong	Received

FRI-361	M480, a novel non-bile acid FXR agonist, shows improvement across multiple parameters in a diet-induced obese mouse model with biopsy-confirmed NASH	Ken Song	Received

FRI-362	Increased non-shivering thermogenesis had preventive but no therapeutic effects on non-alcoholic steatohepatitis	Laurence Poekes	Received

SAT-362	Glucagon-like peptide-1 receptor agonists ameliorate inflammation and fibrosis in an optimized rodent NASH model via inhibition of inflammatory macrophage activation	Xiaoyu Wang	Received

FRI-363	EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis	Li-Juan Jiang	Received

THU-363	Allele frequency of non-alcoholic fatty liver disease-associated PNPLA3 and TM6SF2 polymorphism in a multi-ethnic population of 60,706	Jake Peter Mann	Received

THU-364	Development and validation of automated assessment of liver fibrosis using second harmonic generation microscopy in patients with non-alcoholic fatty liver disease	Jason Chang	Received

SAT-364	High carbohydrate diet induces acute liver injury, enhanced de novo lipogenesis, inflammation and fibrosis but reversible by M2 macrophage polarization	Yong Ook Kim	Received

FRI-364	Extracellular vesicle changes in a diet induced model of non-alcoholic fatty liver disease progression and the role of TNF alpha	Linda A Ban	Received

FRI-365	Kupffer cell pool is maintained by local proliferation and the differentiation of bone marrow monocytes into short-lived monocyte-derived Kupffer cells during non-alcoholic steatohepatitis and recovery	Lindsey Devisscher	Received

THU-365	A pragmatic algorithm to rule out non-alcoholic steatohepatitis in patients at risk of non-alcoholic fatty liver disease in spite of a normal ultrasound	Javier Ampuero	Received

SAT-365	Exosome derived from palmitic acid-treated hepatocytes activates hepatic stellate cells	Young-Sun Lee	Received

SAT-366	Nano LC- mass spectrometry based proteomic profiling associated with significant fibrosis and collagen deposition in non-alcoholic fatty liver disease (NAFLD)	Zobair M Younossi	Received

FRI-366	STK25 is a critical determinant in nonalcoholic steatohepatitis	Margit Mahlapuu	Received

FRI-367	Survival analysis and response to ursodeoxycholic acid in patients with primary biliary cholangitis	Montserrat Garcia Retortillo	Received

SAT-367	Frequent deterioration in autoimmune hepatitis with acute presentation is not associated with acute AIH but acute exacerbation that could be differentiated from acute AIH by surrogate markers for liver fibrosis	Jong-Hon Kang	Received

SAT-368	The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time	Jorn C Goet	Received

THU-368	The anti-human immunodeficiency virus drug rilpivirine decreases hepatic injury in a nutritional model of non-alcoholic fatty liver disease through activation of the IL6/IL22-STAT3-p53 axis	Alberto Martí-Rodrigo	Received

FRI-368	The role of ethnicity in autoimmune hepatitis	Alessio Gerussi	Received

THU-369	Anti-fibrotic effect of NV556, a sanglifehrin-based cyclophilin inhibitor, in a preclinical model of non-alcoholic steatohepatitis	Alvar Grnberg	Received

SAT-369	Prognostic factors for transplant-free survival and external validation of prognostic models in Chinese patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy	Ka Shing Cheung	Received

THU-370	Increased hepatic glucose production and insulin resistance in subjects with non-alcoholic fatty liver disease is associated to increased plasma concentrations of glucogenic amino acids	Amalia Gastaldelli	Received

SAT-370	Clinical and translational outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease receiving vedolizumab	Kate Diana Williamson	Received

FRI-370	Evaluation of 6-thioguanine therapy in autoimmune hepatitis	Floris Frans van den Brand	Received

SAT-371	Enrichment of genetic variants in the glucocorticoid receptor signalling pathway in standard treatment failure autoimmune hepatitis	Peter Lykke Eriksen	Received

THU-371	Activation of miR-34a contributes to liver and muscle insulin resistance in experimental and human non-alcoholic fatty liver disease	Marta B. Afonso	Received

FRI-371	Evaluation of spleen length progression rate as a surrogate marker of clinical outcome in patients with primary sclerosing cholangitis	Franziska Jung	Received

FRI-372	Dysbiosis of the gut microbiota and increased gut permeability characterize secondary sclerosing cholangitis in critically ill patients (SSC-CIP)	Andreas Blesl	Received

THU-372	The immunomodulatory activity of the protease-inhibitor SerpinB3 in vivo and in vitro	Patrizia Pontisso	Received

SAT-372	Long-term outcomes in autoimmune hepatitis patients withdrawing from immunosuppressive therapy	Laura Harrison	Received

SAT-373	The interpretation of follow-up 3D-magnetic resonance cholangiopancreatography/magnetic resonance imaging in patients with primary sclerosing cholangitis is difficult and highly variable even between experienced specialists	Roman Zenouzi	Received

THU-373	Small molecule AXL inhibition prevents diet-induced liver fibrosis and inflammation in experimental models of NASH	Anna Tutusaus	Received

FRI-373	Intradermally applied LPA but not bile salts induce itch and pain in humans depending on the mode of application	Andreas E. Kremer	Received

THU-374	CD40 activation alleviates steatosis in cultured hepatocytes	Antonios Chatzigeorgiou	Received

FRI-374	Low platelet count influences the performance of the different biochemical criteria of ursodeoxycholic acid therapy response in primary biliary cholangitis	Anna Reig	Received

SAT-374	Analysis of shear wave elastography and serum autotaxin as novel non-invasive markers of liver fibrosis in patients with autoimmune hepatitis – a prospective study	Maciej K. Janik	Received

SAT-375	Health related quality of life (HRQoL) in patients with AIH: a prospective, single centre study	Maciej K. Janik	Received

THU-375	The PPARa-regulated dermatopontin is an important contributor to the liver fibrotic response in mouse models and has relevance to fibrosis progression in non-alcoholic fatty liver disease patients	Bart Staels	Received

FRI-375	The novel hexokinase 1 antibodies are useful for the diagnosis and associated with bad prognosis in primary biliary cholangitis	Anna Reig	Received

FRI-376	Primary biliary cholangitis demographics and outcomes: a paradigm shift	George Cholankeril	Received

THU-376	PBI-4050 reduces liver damage and fibrosis in a high-fat diet mouse model of obesity and metabolic syndrome	Brigitte Grouix	Received

SAT-376	A population based analysis of prevalence and treatment of autoimmune liver diseases in Germany	Marcial Sebode	Received

THU-377	A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis	Bryan C Fuchs	Received

FRI-377	Prompt initiation of intravenous corticosteroids prevents deterioration of acute/severe autoimmune hepatitis (AS-AIH) and the need for liver transplantation (LT)	George N Dalekos	Received

SAT-377	Dynamic risk prediction in Primary Biliary Cholangitis using the UK-PBC cohort	Marco Carbone	Received

THU-378	Development of LMB763, a novel, orally bioavailable, clinical farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis and hepatobiliary disorders	Bryan Laffitte	Received

SAT-378	Risk reduction with obeticholic acid in patients not achieving the POISE primary endpoint	Maren Harms	Received

SAT-379	Patient perspectives on living with autoimmune hepatitis - identifying opportunities to improve care	Margaret Corrigan	Received

FRI-379	The health burden of primary biliary cholangitis in Switzerland: a cross-sectional study	Benedetta Chiara Terziroli Beretta-Piccoli	Received

THU-379	Kupffer cell populations share inflammatory tasks and outline a shift in liver resident macrophage population during liver inflammation	Christina Mehrfeld	Received

THU-380	The gut microbiome of lean patients with non-alcoholic steatohepatitis: comparison with overweight/obese counterparts and healthy subjects, correlation with dietary intake and liver histology	Claudia P Oliveira	Received

SAT-380	Non-invasive evaluation of liver fibrosis in autoimmune hepatitis: still a challenge	Maria Lucia Cardoso Gomes Ferraz	Received

FRI-380	Increase in age at diagnosis of primary biliary cholangitis over the last 40 years	Carla Fiorella Murillo Perez	Received

FRI-381	NOD2 variants as novel genetic risk factors for secondary sclerosing cholangitis in critically ill patients	Christoph Jüngst	Received

THU-381	Influence of UCP3 gene polymorphisms on metabolic syndrome and cardiovascular risk in patients with in non-alcoholic fatty liver disease	Claudia P Oliveira	Received

THU-382	Anti-steatotic effects in conjunction with lowering of PNPLA3 mRNA exerted by LXR inverse agonists in human hepatocytes and in rodent models of non-alcoholic fatty liver disease	Claus Kremoser	Received

SAT-382	Early predictive factors of corticosteroids response in patients with severe/acute or fulminant autoimmune hepatitis	Anna Reig	Received

SAT-383	Low rate of new-onset primary biliary cholangitis in a cohort of anti-mitochondrial antibody positive subjects	Stephan Zandanell	Received

FRI-383	TNFa as therapeutic target in autoimmune hepatitis	Claudia S. Bovensiepen	Received

FRI-384	Development of a multivariate model using serum biomarkers to better define primary biliary cholangitis (PBC)-autoimmune hepatitis (AIH) overlap syndrome	Henry H Nguyen	Received

THU-384	Role of the intestinal vitamin D receptor in obesity, adipose tissue inflammation and hepatic lipid accumulation	Daniel Jahn	Received

THU-385	NorUDCA improves liver injury and metabolic situation in mouse models of obesity and steatosis	Daniel Steinacher	Received

SAT-385	Tolerability and efficacy of 6-mercaptopurin in patients with autoimmune liver disease and azathioprine intolerance	Mayada Elnegouly	Received

FRI-385	Diagnosis of autoimmune sclerosing cholangitis in children with autoimmune hepatitis	Cristina Gonçalves	Received

SAT-386	The prognosis ability of GLOBE score in Chinese patients with primary biliary cholangitis	Zheyi Han	Received

THU-386	Protective effect of quercetin treatment on HFD-induced intestinal dysbiosis and barrier dysfunction in an in vivo model of non-alcoholic fatty liver disease	Francisco Jorquera	Received

SAT-387	Elevated baseline igg is a risk factor for on-treatment flares of autoimmune hepatitis in patients in biochemical remission	Neil Halliday	Received

THU-387	Mitochondrial-shaping proteins as specific biomarkers to distinguish alcohol from fat-induced liver toxicity	Elena Palma	Received

THU-388	Hypoxia-inducible factor 2alpha drives the progression of experimental non-alcoholic fatty liver disease by stimulating hepatocyte production of histidine rich glycoprotein	Elisabetta Morello	Received

SAT-388	Geoepidemiology, clinical manifestations and outcome of a large cohort of primary biliary cholangitis patients in Greece	Nikolaos K. Gatselis	Received

FRI-388	Autoimmune hepatitis with normal IgG levels at diagnosis: subtype with a higher rate of successful treatment withdrawal?	Johannes Hartl	Received

FRI-389	Twenty years´ single center experience with non-obstructive sinusoidal dilation	Dharma Budi Sunjaya	Received

SAT-389	Characteristics of Greek male patients with primary biliary cholangitis	Nikolaos K. Gatselis	Received

THU-389	Early increase in ammonia is a feature of non-alcoholic fatty liver disease and the ammonia lowering drug, ornithine phenylacetate (OCR-002) prevents progression of fibrosis in a rodent model	Francesco De Chiara	Received

THU-390	Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score	Francesco Valentini	Received

SAT-390	Incidence and prevalence of primary sclerosing cholangitis in a population-based cohort in Finland	Nina Barner-Rasmussen	Received

FRI-390	Stage of fibrosis and AST Platelet Ratio Index (APRI) as predictors of length of gestation in women with chronic liver disease	Enoka Gonsalkorala	Received

FRI-391	Autoimmune hepatitis in children and adults: a single centre experience	Lisa Perini	Received

THU-391	IVA337, a pan-ppar agonist, reduces non-alcoholic steatohepatitis feature and inhibits the inflammasome in murin models of non-alcoholic steatohepatitis	Guillaume Wettstein	Received

SAT-392	Cathepsin Z variants are associated with progression to end-stage hepatic failure in Japanese patients with primary biliary cholangitis	Nao Nishida	Received

SAT-393	T cell interactions with the biliary epithelium in primary biliary cholangitis	Rachel Emma Etherington	Received

FRI-393	Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease	David N. Assis	Received

THU-393	Liver iron concentration in patients referred for hyperferritinemia: multicenter analysis of the different groups according to HFE mutations and transferrin saturation index, prediction of liver iron overload in Southern Europe	Leire Zubiaurre	Received

THU-394	Genotypic-phenotypic profile of Wilson disease patients in Lebanon: Comparison with regional Arab countries	Aline Kamil El haddad	Received

FRI-394	Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating fecal bile acid composition and signaling	Claudia Daniela Fuchs	Received

SAT-394	Treg conditioning endows activated Teff with suppressor function in juvenile autoimmune liver disease	Rodrigo Liberal*	Received

THU-395	Liver iron overload within a UK based population by sex	Andrew G Mckay	Received

FRI-395	Autoimmune hepatitis patients with poor treatment response have a distinct liver transcriptome: implications for personalised therapy	Ben Millar	Received

SAT-395	The gut microbiota in liver transplanted primary sclerosing cholangitis patients is characterized by exacerbated dysbiosis	Johannes R. Hov	Received

SAT-396	miRNA-21-deficiency reduces liver injury, fibrosis and necroptosis in cholestatic bile duct-ligated mice	Marta Bento Afonso	Received

FRI-396	Obeticholic acid therapy improves cognitive decline in cholestatic liver disease	Ben Millar	Received

THU-396	Simultaneous non-invasive assessment of liver injury and body composition in alpha1-antitrypsin deficiency	Matthias C Reichert	Received

SAT-397	Impact of treatment with Telmisartan plus Propranolol on liver tight junctions in MDR2 -/- knockout mice	Sigrid Schulte	Received

FRI-397	A novel role for BMP9 as a negative regulator of oval cell-mediated regeneration in response to liver damage	Annalisa Addante	Received

FRI-398	Magnetic resonance imaging findings are related with serum and endoscopic markers of disease activity and severity in primary sclerosing cholangitis	Andrea Tenca	Received

SAT-398	Expression of the bile acid receptor TGR5 in livers of PSC patients and Mdr2-/- (Abcb4 -/-) mice	Maria Reich	Received

THU-398	Induced pluripotent stem cell-derived hepatocyte-like cells for study of the TTR protein quality control system	Christoph Niemietz	Received

THU-399	Dual proteotoxic stress promotes liver tumorigenesis via autophagy overload and activation of p62-mTOR-Nrf2 axis	Deniz Kuscuoglu	Received

FRI-399	Expression of the oncofetal marker Nope in the regenerating adult murine liver after disruption of interhepatocytic gap junctions with impaired polarisation via bile duct ligation	Andrea Bowe	Received

FRI-400	ACE2 therapy using a liver-specific AAV vector inhibits chronic biliary fibrosis in mice	Indu G Rajapaksha	Received

THU-400	Genetic variation of PNPLA3 and TM6SF2 associate with hepatocellular carcinoma in patients with alcohol-related cirrhosis	Felix Stickel	Received

SAT-400	Ablation of Notch-signaling via recombination signal binding protein for immunoglobulin kappa j region knockout in liver induces massive damage by impaired intra-hepatic bile duct morphogenesis, cholestasis and necrosis	Umesh Tharehalli Mathada	Received

SAT-401	Melatonin levels are significantly decreased in liver tissues of patients with primary biliary cholangitis	Urszula Wasik	Received

THU-401	A novel algorithm for the management of patients with PiZZ alpha-1 antitrypsin deficiency	Grace Dolman	Received

THU-402	Soluble (s)CD163 a macrophage activation marker is associated with liver disease severity in patients with Wilson´s disease	Henning Groenbaek	Received

SAT-402	MicroRNA expression profiling of peripheral blood B cells from patients with distinct pathologicalstages of primary biliary cirrhosis	Xiaomei Wang	Received

FRI-402	Pediatric autoimmune hepatitis shows a strong increase of intrahepatic Tregs and an IL-2 associated Treg decline under therapy	Jana Diestelhorst	Received

SAT-403	Identification of Twinfilin-1 as a key regulator of cholangiocyte biological response to injury: evidence for a possible role of ageing in the progression of cholangiopathies	Luca Maroni	Received

THU-403	Assessment of bile salt export pump (BSEP) inhibition by BSEP-reactive immunoglobulins from Antibody-induced BSEP deficiency patients using a novel, cell-based assay	Jan Stindt	Received

FRI-403	Circulating fibroblast growth factor 19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis	Jian Luo	Received

THU-404	Macrophage activation in patients with wilsons disease – associations with metabolic liver function, liver disease severity and fibrosis	Jessica Almida Ellinor Björklund	Received

SAT-404	Exploring the role of macrophages in primary sclerosing cholangitis	Yung-Yi Chen	Received

FRI-404	Exhaustive blood immune phenotype of patients with autoimmune hepatitis	Amédée Pablo Renand	Received

SAT-405	Dysregulated bile salt homeostasis in patients with chronic intestinal failure on home parenteral nutrition	Kiran V.K. Koelfat	Received

THU-405	Transcriptomic analysis reveals novel insights into the effect of therapeutic venesection in HFE haemochromatosis	John Denis Ryan	Received

THU-406	Elevated faecal free iron content in HFE haemochromatosis is reduced by therapeutic venesection	John Denis Ryan	Received

SAT-406	Bacterial translocation after liver transplantation is associated with biliary complications	Jasmijn Wieke Selten	Received

FRI-406	A protective role of IL-22BP in acute liver injury	Anastasios D. Giannou	Received

FRI-407	Neutrophil-to-lymphocyte ratio as an independent predictor of mortality in critically ill cirrhotic patients	Caroline Lemaitre	Received

THU-407	Multi-center study of liver disease in alpha1-antitrypsin deficiency: non-invasive evaluation of liver fibrosis in homozygous PiZZ patients	Karim Hamesch	Received

SAT-407	Plasma expansion is key for sustained liver function and viability during normothermic and subnormothermic ex vivo machine perfusion in a rat model	Joseph Maria George Gassner	Received

THU-408	Heterozygous carriage of the alpha1-antitrypsin Z variant rs28929474 predisposes to the development of cirrhosis in the presence of alcohol misuse and non-alcohol-related fatty liver disease	Karim Hamesch	Received

FRI-408	Etiology, outcome and predictors of mortality of viral related acute liver failure: a single centre prospective cohort study	Chetan Ramesh Kalal	Received

SAT-408	Upregulation of MATE-1 transporter by obeticholic acid correlates with increased biliary excretion of asymmetric dimethylarginine during hepatic ischemia/reperfusion injury	Laura Giuseppina Di Pasqua	Received

FRI-409	Combining renewable human liver tissue and novel extracorporeal devices to deliver mammalian liver support	David Hay	Received

FRI-410	Tapered steroid treatment leads to distinct ALT response patterns in patients with acute severe hepatitis, and may help to distinguish AIH from DILI	Elisabeth Mohr	Received

THU-410	GANAB mutations: a possible lead to a common hepatic cystogenesis pathway in autosomal dominant polycystic kidney and liver disease?	Liyanne Francisca Maria Van De Laarschot	Received

SAT-410	MiRNA 181a and 148a plasma levels during acute cellular rejection in liver transplantation	Pablo Ruiz	Received

SAT-411	Amplification of long noncoding RNA OTUD7AP1, targeted by miRNA 125b, promotes proliferation in hepatocellular carcinoma	Ping Chen	Received

THU-411	Whole genome sequencing analysis of familial primary sclerosing cholangitis	Magdalena Budzinska	Received

FRI-411	Liver progenitors and hematopoietic stem cells in acute liver failure and cirrhosis	Estela Solanas	Received

FRI-412	The Role of chemokine (C-C motif) ligand 2 and the diet influence in the energy metabolism	Fedra Luciano	Received

SAT-412	Impaired liver regeneration following hepatectomy and bleeding is associated with a shift from hepatocyte proliferation to hypertrophy	Rinat Abramovitch	Received

THU-413	New molecular classification of hepatoblastoma through an integrative genomic and transcriptomic study	Marina Simon-Coma	Received

FRI-413	Human hepatobiliary progenitor cells as new candidates for liver cell therapy	Giuseppe Mazza	Received

FRI-414	IL-33 protects Murine viral fulminant hepatitis by targeting coagulation hallmark protein Fgl2/Fibroleukin expression	Haijing Yu	Received

THU-414	Variants in TM6SF2 and PCSK7 are risk factors for the development of cirrhosis in people with genetic haemochromatosis	Marsha Y Morgan	Received

SAT-414	Donation mode impacts on invariant natural killer T cell population leading to scarce iNKT cells in donation after cardiac death liver grafts despite a significant increase in B cells and CD1d expression	Yasmeen Giuma Ghnewa	Received

SAT-415	The nucleoprotein High-mobility group box 1 critically regulates the immune response to bacterial infection	Annika Volmari	Received

THU-415	Inherited prothrombotic risk factors in children with extrahepatic portal vein obstruction: a case-control study	Massimo Primignani	Received

THU-416	Association between GNPAT genotypes and serum iron parameters in C282Y homozygous and C282Y/H63D compound heterozygous patients	Moritz Tobiasch	Received

FRI-416	Augmenter of liver regeneration protects against carbon tetrachloride-induced liver injury by promoting the autophagy in mice	Hongbo Shi	Received

SAT-417	Characterisation of cell-type-specific responses in the liver towards IL-1ß by a mathematical model for the p38MAPK/MK2 pathway	Stephanie Wolf	Received

FRI-417	Formation of bile canaliculi in liver progenitor cell-derived hepatocytes determines clinical outcome of acute-on-chronic liver failure	Xiaodong Yuan	Received

THU-417	Antibiotics induce remission in pediatric PSC-AIH overlap syndrome allowing corticosteroid-free therapy	Pauline Sambon	Received

FRI-418	Evaluation of spheroid reservoir bioartificial liver with porcine hepatocytes in rhesus monkey model of acute liver failure	Ji Bao	Received

THU-418	Clinical outcomes in polycystic liver disease comparing autosomal dominant polycystic liver disease with autosomal polycystic kidney disease: results of the PLD registry	Rene Van Aerts	Received

THU-419	GMP-level isolation, quality assessment and biosafety distribution evaluation on human amnion epithelial cell for cell-based therapies	Roberto Gramignoli	Received

SAT-419	GW4064 alleviate mitochondrial dysfunction and intestinal epithelial cell apoptosis through farnesoid X receptor protected lipopolysaccharides-induced acute intestinal inflammation	Hsuan Miao Liu	Received

FRI-419	The hepatoprotective cytokine Cardiotrophin-1 (CT-1) attenuates inflammation and prevents the systemic effects of endotoxemia by promoting M2 macrophage polarization	Jose Miguel Vélez-Ortiz	Received

THU-420	Identification of Src tyrosine kinase as a therapeutic target in cystic fibrosis liver disease using patient specific induced pluripotent stem cells -derived cholangiocytes	Romina Fiorotto	Received

SAT-421	Impact of sex and apolipoproteins on macrophage activation and Entamoeba histolytica induced liver damage	Jill Noll	Received

FRI-421	Acute on chronic liver failure (ACLF ) – combining CLIF-SOFA criteria with APASL definition of ACLF enhances prediction of mortality at 1, 3 and 6 months	Krishnadas Devadas	Received

FRI-422	Development of human liver extracellular matrix hydrogel for three dimensional cell culture and cell transplantation	Luca Frenguelli	Received

THU-422	Fontan-associated liver disease: diagnosis by elastography and laparoscopic liver biopsy	Yohei Koizumi	Received

SAT-422	Involvement of TA and ?N p63 and p73 isoforms on the regulation of cell death and tumour recurrence in patients with hepatocarcinoma submitted to liver transplantation	Jordi Muntané	Received

FRI-423	Exacerbated LPS/GalN-induced liver injury in the stress sensitive Wistar Kyoto rat: possible role of the endocannabinoid system?	Marykate Killilea	Received

SAT-423	Hepatitis B virus infected cell slows down its cell cycle and proliferation by viral protein and replication	Kenichi Morikawa	Received

THU-423	Prognostic value and prediction of extra-tumoral microvascular invasion among patients who candidate for hepatectomy or liver transplantation for hepatocellular carcinoma	Hidetoshi Nitta	Received

FRI-424	Long term mortality is increased in patients surviving acute liver failure without liver transplantation	Mhairi C Donnelly	Received

THU-424	Ischaemic-reperfusion injury and different risk factors for acute kidney injury in donation after circulatory death liver transplantation. UK single centre study	Ilaria Umbro	Received

SAT-424	EZH2 methyltransferase and JMJD3/UTX demethylases are involved in hepatocytic differentiation and liver cancer cells plasticity	Laura Belloni	Received

FRI-425	Genetic ablation of pannexin1 protects against acetaminophen-induced hepatotoxicity in mice	Michaël Maes	Received

SAT-425	SLU7 is a survival factor for cancer cells working as a mitotic regulator	Maddalen Jimenez	Received

FRI-426	Hepatocyte-specific deletion of type I interleukin-1 receptor (IL-1RI) attenuates D-GalN/LPS-induced acute liver injury in vivo	Nadine Gehrke	Received

SAT-426	p38-alpha MAPK couples inflammatory response and proliferation of hepatocytes during acute liver injury	Manon Fortier	Received

THU-426	Long term prevention of recurrent hepatitis B after liver transplantation using nucleos(t)ide analogs after HBIg discontinuation	James Vu	Received

THU-427	No increase in graft fibrosis for hepatitis B surface antigen positive patients after liver transplantation using entecavir monotherapy	James Yan Yue Fung	Received

SAT-427	Amino-functionalized nanoparticles as a platform for mTOR activity modulation in hepatocellular carcinoma Huh7 cell line	Mariia Lunova	Received

FRI-427	Melatonin protects liver in experimental severe acute liver failure	Norma Anair Possa Marroni	Received

FRI-428	Hepatic accumulation and activation of CD8+ T cells aggravate acute liver injury	Patricia Maria Niemietz	Received

THU-428	Pregnancy outcomes in the post liver transplant setting: The Irish experience	Jayne Doherty	Received

THU-429	Sarcopenia is associated with increased hospital expenditure in patients undergoing major cancer surgery of the alimentary tract	Jeroen Van Vugt	Received

SAT-429	Reduced miR-26b-5p expression imparts malignant features and help in EpCAM+ liver cancer stem-like cells maintenance via heat shock cognate 71kDa protein (HSC71/HSPA8)	Ritu Khosla	Received

SAT-430	Implications of Unc5A depletion for hepatocyte survival in chronic liver diseases upon induction of the unfolded protein response	Romain Barnault	Received

FRI-430	Experimental approach to IGF-1 therapy in acute liver damage: acute injury by carbon tetrachloride in controls and mice with partial IGF-1 deficiency	Rocío García de la Garza	Received

THU-430	Progression of familial amyloidosis after domino liver transplantation in donor and recipient	Johanna Vollmar	Received

FRI-431	CX3CR1 modulates the differentiation of monocyte-derived inflammatory dendritic cells in response to hepatic injury	Stefania Bruzzi	Received

THU-431	Clinical outcomes of patients delisted from the waiting list of liver transplantation after interferon-free antiviral therapy	Juan Manuel Pascasio	Received

THU-432	Donor mannose-binding lectingene polymorphisms increase the risk of severe bacterial infections after liver transplantation	Julissa Lombardo	Received

FRI-432	External validation of the USALFSG acute liver failure outcome prediction criteria	William Bernal	Received

SAT-432	Microphysiological systems for studying interactions between the liver, gut and immune system	Tomasz Kostrzewski	Received

SAT-433	Combined targeting of cholangiocytes and activated stromal cells with a BH3 mimetic ameliorates fibrosis in a mouse model of PSC	Anja Moncsek	Received

THU-433	Pregnancy outcomes in liver transplant recipients: a single tertiary centre experience	Katherine Johanna Arndtz	Received

FRI-433	The role of bacterial infection (BI) in decompensated cirrhosis patients with or without acute-on-chronic liver failure (ACLF)	Zhujun Cao	Received

FRI-434	NOX4 dependent activation of hepatic stellate cells with conditioned medium derived from Isoniazid treated hepatocytes: an In-vitro study	Abhijit Chowdhury	Received

SAT-434	Aging enhances liver fibrotic response in mice through hampering extracellular matrix remodeling	Benedicte Delire	Received

THU-434	Effect of diabetes and obesity on short-term outcome after major liver resection	Katrin Hoffmann	Received

SAT-435	The dynamic roles of hepatocyte and leukocyte-specific CD147 in a progressive liver injury mouse model	Christine Yee	Received

THU-435	Occult Hepatitis B Virus persistence in liver transplant recipients despite prophylactic hepatitis B immune globulin and potent nucleos/tide analogues therapy	Keith CK Lau	Received

FRI-435	Alpha toocotrienol causes apoptosis of activated hepatic stelate cells through lysosome mitochondrial axis in INH induced liver fibrosis: an in-vitro study	Abhijit Chowdhury	Received

FRI-436	TAK1 signaling is essential for NLRP3 activation in mouse drug-induced damage-associated hepatitis	Bibo Ke	Received

SAT-436	Comparison of liver injury evolution in mouse models	Christine Yee	Received

THU-436	A pospective study to evaluate the impact of early everolimus on the recurrence of hepatocellular carcinoma after liver transplantation	Manuel Rodríguez-Perálvarez	Received

SAT-437	CD5L modulates primary human hepatic stellate cells activation	Cristina Barcena	Received

THU-437	Impact of "rescue allocated" livers on outcomes after liver transplantation: a propensity score matching analysis	Mara Disabato	Received

FRI-437	The novel macrophage activation marker soluble Mannose Receptor, and soluble CD163, are elevated after acetaminophen intoxication in relation to liver disease severity	Cecilie Brøckner Siggaard	Received

THU-438	Medical emergency team activation in patients pre- and post-liver transplantation is associated with prolonged length of stay and higher morbidity	Marcus Robertson	Received

SAT-438	Induced pluripotent stem cells-derived extracellular vesicles shuttle bioactive molecules with anti-fibrotic potential in vitro and in vivo	Davide Povero	Received

FRI-438	Characterisation of the immune response in patients with drug induced liver injury	Giacomo Germani	Received

SAT-439	The vacuolar adenosine tri-phosphatase (v-ATPase) proton pump as therapeutic target in human activated HSC	Giusi Marrone	Received

THU-439	Interferon-free therapy is effective and safe for hepatitis C recurrence in liver transplant hepatitis C virus/human immunodeficiency virus coinfected recipients: A case-control study	Xavier Forns	Received

FRI-439	Drug-induced effects on mtDNA homeostasis in HepaRG cells and modulation by steatosis	Dounia Le Guillou	Received

FRI-440	p62/sqstm1 in a drug-induced model of hepatotoxicity: a novel role beyond autophagy	Fernando Alegre	Received

THU-440	The golden hour: length of total warm ischemia time presages development of severe acute kidney injury after DCD liver transplantation	Marit Kalisvaart	Received

SAT-440	Kahweol attenuates hepatic fibrosis by inhibition of CTGF via TGF-ß signaling pathways	Byoung Kuk Jang	Received

SAT-441	Non-sense mediated RNA decay regulates the unfolded protein response during hepatic stellate cell activation	Inge Mannaerts	Received

THU-441	The use of prophylactic strategies using hepatitis B immunoglobulin for hepatitis B recurrence after liver transplantation in routine clinical practice in Spain. preliminary results of the 1st round of a delphi panel	Martín Prieto	Received

FRI-441	The S-ademetionine role in the prevention of liver injury in patients with acute leukemias in the polychemotherapy dynamics	Igor Skrypnyk	Received

FRI-442	Reprogramming of human umbilical cord-derived mesenchymal stromal cells into hepatocyte-like cells by over-expression of hepatocyte nuclear factor 1-alpha	Karolien Buyl	Received

THU-442	Entecavir or tenofovir monotherapy prevents hepatitis B virus recurrence in liver transplant recipients: a 5-year follow-up study after hepatitis B immunoglobulin withdrawal	Matteo Angelo Manini	Received

SAT-442	Local environment in cirrhotic liver induces Th2 polarization of CD4+ cells which amplify fibrogenesis by activating hepatic stellate cells	Johanna Antonia Reissing	Received

SAT-443	Ammonia elevates B-neurexin in hepatic stellate cells to escape NK cells activity	Johnny Amer	Received

THU-443	The incidence of metabolic syndrome and the association with its clinical consequences after liver transplantation	Milou Mireille Ter Avest	Received

FRI-443	Free cholesterol accumulation in liver sinusoidal endothelial cells exacerbates acetaminophen hepatotoxicity in mice	Kengo Tomita	Received

FRI-444	Clinical characteristics and outcomes of elderly included in the Spanish Drug-Induced Liver Injury (DILI) Registry	Raùl J Andrade	Received

THU-444	Differences in the occurrence of metabolic syndrome between patients treated with a calcineurin inhibitor and patients treated with an mTOR inhibitor after liver transplantation	Milou Mireille Ter Avest	Received

SAT-444	Genome wide methylation profile of liver from patients with severe hepatic fibrosis related to HCV infection	Luydson Vasconcelos	Received

SAT-445	Autophagy regulates endothelial dysfunction and hepatic fibrosis development	Maria Ruart	Received

FRI-445	Prevalence and severity of liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients	Antonio Grieco	Received

FRI-446	Jnk2 is indispensable in murine and human Ibuprofen-induced acute liver failure	Miguel Eugenio Zoubek	Received

THU-446	The association of the metabolic syndrome with cardiovascular and cerebrovascular outcomes and renal dysfunction after liver transplantation	Olivia FH Ho	Received

SAT-446	How gender influences fibrosis regression in a chronic murine model of hepatic injury	Marika Crescenzi	Received

SAT-447	Activated primary stellate cells show decreased aquaporin 3 expression in parallel with cellular senescence which is restored with PPAR-? agonist establishing quiescence	Matteo Tardelli	Received

THU-447	Impact of hepatitis C virus treatment on renal function in liver transplant patients	Omar Massoud	Received

FRI-447	Development of a novel 3D organotypic human HepaRG-based non-invasive imaging platform for pre-clinical drug screening	Nicole Jenna Martucci	Received

SAT-448	Differential role of NLRP3 inflammasome during acute and chronic cholestatic liver injury	Mick Frissen	Received

THU-449	Preoperative von willebrand factor - antigen predicts clinical outcome after liver resection: a prospective, international, multicenter trial	Patrick Starlinger	Received

FRI-449	Drug-induced liver injury: presentations, causes and outcomes: an Egyptian study	Omkolthoum Alhadad	Received

THU-450	Nurse-led self-management support across two hospitals in liver transplantation: a win-win situation for patients and health care professionals	Patrizia Künzler-Heule	Received

SAT-450	Immunofluorescence identifies distinct subsets of endothelial cells in the human liver	Otto Strauss	Received

FRI-450	Influence of host characteristics and pharmacological properties on type of liver injury in hepatotoxicity	Raul Andrade	Received

FRI-451	Liver progenitor cells significantly contribute to hepatocyte pool in chronic liver injury and cirrhosis: a kinetic study in mice	Rita Manco	Received

THU-451	History of marijuana use does not affect outcomes on the liver transplant waitlist	Prashant Kotwani	Received

SAT-451	Inhibition of canonical WNT signaling pathway by ß-catenin/CBP inhibitor ICG001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12	Ruchi Bansal	Received

FRI-452	Benzo[a]pyrene and ethanol exert a high toxicity potential in steatotic HepaRG cells: possible role of low NDUFA4L2 expression	Simon Bucher	Received

SAT-452	Antifibrotic effects of 8-hydroxydeoxyguanosine through the inhibition of NADPH oxidase-derived oxidative stress in vitro and in vivo model of liver fibrosis	Seung Kak Shin	Received

THU-452	The effect of beta-hydroxy-beta-methyl butyrate supplementation on muscle wasting in patients undergoing liver transplantation: results of preliminary analysis	Rosanna Lacetera	Received

THU-453	Hyperfibrinolysis during liver transplantation detected by classical parameters and thromboelastometry	Sara Maggiolo	Received

FRI-453	Modelling the impact of targeted interventions on the HCV epidemic in Pakistan: the road to HCV elimination	Aaron G. Lim	Received

FRI-454	The evaluation of homelessness on HCV treatment outcomes among current and former people who inject drugs	Arshia	Received

SAT-454	The anti Fibrotic effect of Aramchol on liver Fibrosis in TAA animal model	Shimon Reif	Received

SAT-455	A novel 3D Liver Microtissue Model for studying steatosis in vitro	Simon Messner	Received

THU-455	Implementation of psycho-social electronically-captured patient-reported outcome measures for liver transplant at Mayo Clinic Florida	Shehzad Khan Niazi	Received

FRI-455	Pilot validation study of a rapid test in oral fluid for population screening of hepatitis C virus infection	Carmina Pallarés	Received

FRI-456	Rapid and large implementation of HCV treatment advances in France, 2007-2015	Christine SILVAIN	Received

SAT-456	In bone marrow derived macrophages hepatocyte trigger a marker pattern that is indicative for alternatively activated, regulatory type macrophages	Stephanie Wolf	Received

THU-456	MELD score > 19 on day five after liver transplant in hepatitis C virus-positive recipients: impact on 90-day graft loss and analysis of predictors	Silvia Martini	Received

SAT-457	FOXA2 overexpressed adipose derived stem cells attenuated acute liver injury model	Yeon Ji Chae	Received

THU-457	Favourable virological and clinical outcomes at 1 year after liver transplantation in hepatitis C virus-positive patients who received direct-acting antivirals on the waiting list	Silvia Strona	Received

FRI-457	Screening for HCV in pregnant women and their partners	Charlotta Millbourn	Received

THU-458	Risk of late-onset CMV infection after liver transplantation is associated with recipient´s IFNL4 rs12979860 genotype	Sona Franková	Received

SAT-458	Dabigatran reduces liver fibrosis in thioacetamide-injured rats	Yun-Cheng Hsieh	Received

SAT-459	A novel FXR agonist EDP-305 potently suppresses liver injury and fibrosis in mouse models of biliary and metabolic liver disease	Yury Popov	Received

THU-459	Evolution of body weight parameters up to 3 years after liver transplantation: the prospective Swiss transplant cohort study	Sonja Beckmann	Received

THU-460	Liver transplantation does not impact the renal function outcome in Alagille syndrome	Tanguy Demaret	Received

FRI-460	HCV elimination among people who inject drugs. What would happen after the WHO HCV elimination target is achieved?	Ilias Gountas	Received

SAT-460	Morphology based assessment of liver fibrosis using a new quantitative metric in abdominal CT scans	Andreas Christe	Received

FRI-461	Treatment and primary prevention in people who inject drugs (PWID) for chronic Hepatitis C (CHC): Is elimination possible in a high prevalence setting?	Ilias Gountas	Received

THU-461	The risk of death after liver transplantation due to increasing donor age is highest in young recipients	Therese Bittermann	Received

SAT-461	Soluble CD147 has an altered expression profile with liver disease progression and in different ethnicities	Aimei Lee	Received

SAT-462	Non invasive diagnostic modalities to predict advanced hepatic fibrosis in patients with non alcoholic fatty liver disease: a retrospective study	Ajeet Singh Bhadoria	Received

FRI-462	The impact of broader hepatitis C treatment strategies on population health and social value in England	Alison Silverstein	Received

THU-462	The burden of healthcare utilization after liver transplantation and its relationship with pre-transplant hospitalization	Therese Bittermann	Received

FRI-463	Integrating voluntary hepatitis B, C and HIV screening in the compulsory tuberculosis entry screening for immigrants, The Netherlands: a pilot project	Janneke Bil	Received

SAT-463	Risk of liver fibrosis in patients with Thalasemia major; a tertiary center experience	Alghalya A Alomairi	Received

THU-463	Recurrence of primary sclerosing cholangitis is associated with lower survival after liver transplantation: an analysis of the European liver transplant registry data base	Thijmen Visseren	Received

SAT-464	Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis	Alina M. Allen	Received

FRI-464	Access to hepatitis C treatment in Europe: findings from the 2016 Hep-CORE study	Jeffrey Victor Lazarus	Received

THU-465	A glycomic serum marker analysed at one week after liver transplantation is an independent predictor of graft loss during the first year after liver transplantation	Xavier Verhelst	Received

FRI-465	Do elevated liver values necessarily indicate a health problem or could poorly defined upper limits of normal be an issue? Alanine aminotransferase and gamma-glutamyltransferase depend strongly on age	Johannes Wiegand	Received

SAT-465	Acoustic Radiation Force Imaging the Fontan liver – feasibility and reproducibility	Amanda J Nicoll	Received

THU-466	Pretransplant glycomic analysis of perfusate is predictive of primary non function after liver transplantation	Xavier Verhelst	Received

SAT-466	The clinical utility of non-invasive tests in cirrhosis: results of decision analysis modelling	Avik Majumdar	Received

FRI-466	Hepcheck Dublin: homeless, hepatitis C & competing priorities	John S Lambert	Received

FRI-467	Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia	Julie Bouscaillou	Received

SAT-467	Prevalence of fatty liver and fibrosis in patients with type 2 diabetes mellitus and previously undetected liver disease as assessed by transient elastography and ultrasound	Ivica Grgurevic	Received

THU-467	Inhibition of NADPH oxidase-2 and P38 mitogen activated protein kinase suppresses acrolein aggravated hepatic ischemia reperfusion injury through neutrophil extracellular traps	Arumugam Suyavaran	Received

SAT-468	Non-invasive detection of patients with nonalcoholic steatohepatitis at risk of adverse liver outcomes	Jagpreet Chhatwal	Received

FRI-468	Smoking and metabolic syndrome components are independent predictors of mortality in patients with chronic liver disease in the United States	Karn Wijarnpreecha	Received

SAT-469	ECV-associated miRNA levels as non-invasive biomarkers for early-stage HBV/HCV-induced liver fibrosis	Joeri Lambrecht	Received

THU-469	Herpesviruses in bile: Increasing sensitivity by testing the right compartment	Conrad Rauber	Received

FRI-469	Chronic hepatitis C diagnosis increases sick leave and disability pension	Jonas Söderholm	Received

THU-470	Simulated microgravity significantly impacts the differentiation and metabolism of human hepatic and biliary tree stem/progenitor cells	Daniele Costantini	Received

FRI-470	Inadequate identification of fatty liver disease, obesity, and metabolic syndrome by family physicians	Mahmud Mahamid	Received

SAT-470	Non-invasive fibrosis markers are independent predictors of mortality among U.S. adults with nonalcoholic fatty liver disease	Karn Wijarnpreecha	Received

SAT-471	Association between non-invasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease in the United States	Karn Wijarnpreecha	Received

THU-471	The role of recipient epithelial cells in regeneration after liver transplantation: different kinetics of chimerism for hepatocytes and bile duct epithelial cells	Floris Johan Maria Roos	Received

FRI-471	A survey on non-alcoholic fatty liver disease amongst general practitioners: time to bridge the gap between hepatologists and primary care	Jef Verbeek	Received

FRI-472	Identification of the healthy ranges for enhanced liver fibrosis score	Agostino Colli	Received

THU-472	Approaches to fabricate practical recellularized liver graft using primary liver cells-our seeding method for optimal distribution of parenchymal and endothelial cells	Hidenobu Kojima	Received

SAT-472	Non-invasive evaluation of clinically significant portal hypertension: validation of two novel algorithms combining liver and spleen stiffness using shear-wave elastography in a large independent cohort of patients with cirrhosis	Laure Elkrief	Received

SAT-473	Elastogram quality assessment score in vibration controlled transient elastography: diagnostic performance compared to digital morphometric analysis of liver biopsy	Leandro Cesar Mendes	Received

FRI-473	Non-steroid anti-inflammatory drugs for biliary colic	Mirella Fraquelli	Received

THU-473	Human leukocyte antigen matching in living donor liver transplantation: does it affects the outcome?	Iman Montasser	Received

SAT-474	Ultrasound-measured visceral adipose tissue correlates with risk factors, severity and co-morbidities of NAFLD better than waist circumference	Lucia Napoli	Received

THU-474	Bile duct strictures after liver transplantation are associated with a donor glypican-6 polymorphism linked to the biliary stem cell niche	Jasmijn W. Selten	Received

FRI-474	Hepatitis prevention, control, and elimination program in Mongolia: National hepatitis elimination program in a country with the highest burden of viral hepatitis in the world	Naranbaatar Dashdorj	Received

FRI-475	Reaching hepatitis C virus elimination targets in Australia requires use of complementary cost-effective interventions along the care cascade	Joseph Doyle	Received

SAT-475	Controlled attenuation parameter predicts steatosis in alcoholic liver disease and correlates with poor metabolic phenotype and cardiovascular risk: A biopsy-controlled multicenter study	Maja Thiele	Received

THU-475	The non-alcoholic fatty liver disease liver fat score is associated with liver disease mortality in the United States population	Aynur Unalp-Arida	Received

SAT-476	Transient elastography correlates with liver fibrosis and markers of portal hypertension in PSC: Laennec score-based analysis of explanted livers	Marcin Krawczyk	Received

FRI-476	Eliminating hepatitis C virus from HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour	Joseph Doyle	Received

THU-476	The impact of bariatric surgery on nonalcoholic fatty liver disease and cardiovascular risk utilizing non-invasive measures	Carmit Netanel	Received

THU-477	Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease	Caussy Cyrielle	Received

FRI-477	Implementing the WHO Global Health Sector Strategy on Viral Hepatitis in Denmark – modeling the effects of community-based care on the elimination of HCV by 2030	Ole Henriksen	Received

SAT-477	Effect of meal ingestion on liver stiffness and controlled attenuation parameter	Marco Silva	Received

FRI-478	An alternative screening strategy for hepatitis C virus infection among americans not belonging in the baby boomer birth cohort	Prowpanga Udompap	Received

THU-478	Noninvasive diagnosis of hepatic fibrosis by biofibroscore in patients with chronic hepatitis C virus infection	Chen-Hua Liu	Received

SAT-478	Dynamics of liver stiffness and serum IP10 levels among patients with chronic hepatitis C who achieved SVR with DAA treatment	Cristina Rigamonti	Received

SAT-479	Predictors of persistence of clinical significant portal hypertension in patients with HCV liver cirrhosis following 3D therapy and SVR	Maria C. Speranta Iacob	Received

THU-479	Screening for nonalcoholic fatty liver disease by transient elastography with controlled attenuation parameter in unselected patients with inflammatory bowel disease	Chiara Saroli Palumbo	Received

FRI-479	Effectiveness and cost-effectiveness of antiviral treatment initiation in hepatitis C related decompensated cirrhosis in France	Sylvie Deuffic-Burban	Received

FRI-480	Systematic screening in an ongoing cross-sectional epidemiological study on hepatitis C high-risk populations in Trondheim city, Norway	Therese Svendsen	Received

THU-480	Liver stiffness based model predicts portal hypertension, esofageal varices and hepatocellular carcinoma in caucasian patients with hepatitis B virus-related cirrhosis responsive to antiviral therapy	Claudia Chialà	Received

SAT-480	Circulating Fibroblast Activation Protein activity as a liver fibrosis biomarker in NAFLD	Geoffrey William McCaughan	Received

THU-481	Variability of intrahepatic fat distribution and optimal measurement of hepatic fat amount using MRI proton density fat fraction	Dae Won Jun	Received

SAT-481	Point shear wave elastography (ElastPQ) is a reliable non-invasive tool for the diagnosis and characterisation of portal hypertension	Matteo Rosselli	Received

FRI-481	Prevalence of end of life criteria in patients with liver disease in South West England	Ulrich Thalheimer	Received

FRI-482	High levels of transmission of HCV infection among people who inject drugs in Greece	Vana Sypsa	Received

SAT-482	Prospective comparison of shear-wave elastography, CAP and conventional ultrasound for non-invasive detection and grading of steatosis	Maxime Ronot	Received

THU-482	Acoustic radiation force impulse elastography combined with ultrasound spleen platelets portal vein doppler score in variceal screening: Improved performance compared with baveno VI criteria for avoidance of endoscopy in cirrhotics	David Ian Sherman	Received

THU-483	The role of serial ARFI elastography in confirming remission in active autoimmune liver disease: a controlled study with long follow up	David Ian Sherman	Received

FRI-483	High prevalence of chronic hepatitis C in injecting drug users in Tanzania, East Africa: a neglected burden of disease	Zameer Mohamed	Received

FRI-484	Novel PCR-based method to detect fungal colonization of ascites, bile and duodenal fluid in patients with acute on chronic liver failure (ACLF) or after orthotope liver transplantation (OLT)	Adam Herber	Received

THU-484	ElastPQ shear-wave elastography compared to fibroscan transient elastography for fibrosis staging in patients with NAFLD	Davide Roccarina	Received

SAT-484	The point of care 13C-Methacetin breath test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology	Mitchell L. Shiffman	Received

SAT-485	The hidden burden of hepatitis C related advanced liver disease in the community	Nadeem Iqbal	Received

THU-485	Delayed decrease of splenic stiffness in chronic hepatitis C virus patients receiving direct-acting antivirals	Dina Attia	Received

FRI-485	Model for end stage liver disease score dynamics in NASH patients awaiting liver transplantation and waitlist outcomes	W. Ray Kim	Received

FRI-486	Model for end stage liver disease score dynamics in patients awaiting liver transplantation and waitlist outcomes	W. Ray Kim	Received

THU-486	Urinary metabotypes in patients with chronic hepatitis C virus infection as revealed by nuclear magnetic resonance-based metabolomics	Elisa Biliotti	Received

SAT-486	Attenuation coefficient measurement as novel real time ultrasound alternative to CAP (fibroscan)	Nataliia Marunchyn	Received

SAT-487	How to combine blood test and elastography to stage liver fibrosis in chronic hepatitis C?	Paul Cales	Received

FRI-487	External validation of the HCC-MELD score for patients with hepatocellular carcinoma waiting for liver transplantation	Alessandro Vitale	Received

THU-488	Noninvasive assessment of liver fibrosis and portal hypertension after viral eradication in post-transplant hepatitis C	Ezequiel Mauro	Received

SAT-488	Comprehensive NAFLD diagnosis based on a noninvasive metabolomic approach in a liquid biopsy	Puneet Puri	Received

FRI-488	Sofosbuvir based therapy for recurrent hepatitis C post liver transplantation: an Egyptian experience	Ayman Yosry	Received

FRI-489	The impact of multidisciplinary support to alcohol misusers at risk of alcohol relapse after liver transplantation	Barbara Lattanzi	Received

THU-489	Normal values of liver stiffness as measured by transient elastography: pooled individual participant data meta-analysis from 26 studies and 14,883 participants	Kymberly D. Watt	Received

THU-490	Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens	Federico Ravaioli	Received

SAT-490	Serum Pro-C3 combined with clinical parameters is superior to established serological fibrosis tests at identifying patients with advanced fibrosis among patients with Non-alcoholic fatty liver disease	Samuel Joseph Daniels	Received

FRI-490	A tele-health based technology can effectively triage liver transplant evaluations and minimize futile invasive testing in an integrated health deliver system	Binu John	Received

FRI-491	Prospective comparison of coefficient attenuation parameter and ultrasound for grading graft steatosis in a large real-life cohort of liver-transplant patients	Christiane Stern	Received

SAT-491	Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in obese patients with non-alcoholic fatty liver disease	Sander Lefere	Received

THU-491	DAAs treatment in hepatitis C virus recurrence after Liver Transplantation: clinical usefulness of non-invasive methods	Federico Ravaioli	Received

THU-492	Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients	Federico Ravaioli	Received

FRI-492	Cardiovascular risk and coronary artery calcium score after liver transplantation: study at fouth year	Claudia P Oliveira	Received

SAT-492	The assessment of liver fibrosis stage by two-dimensional shear wave ultrasound and transient elastography in patients with chronic liver disease	Sang Gyune Kim	Received

THU-493	Which are the best cut-off values for predicting different stages of liver fibrosis for 2D-SWE.GE in daily practice?	Felix Bende	Received

SAT-493	Circulating serum exosomal microRNA-203 as a non-invasive biomarker for predicting prognosis in hepatocellular carcinoma	Se Young Jang	Received

FRI-493	Auxiliary liver transplantation for acute liver failure: a model of competition between regeneration and apoptosis	Clémence Hollande	Received

FRI-494	Preoperative intra-platelet serotonin levels are associated with early disease recurrence after liver resection in humans	David Pereyra	Received

THU-494	Non-invasive assessment of liver fibrosis by point share wave elastography in primary biliary cholangitis: comparison with fibroscan and fibrosis scores	Francesca Saffioti	Received

SAT-495	Community Approach Targeting Cirrhosis and Hepatocellular carcinoma (CATCH): Community prevalence of advanced fibrosis in viral hepatitis	Stephen Bloom	Received

THU-495	Predictive value of S-GGT for severe liver disease in the general population – a population-based cohort study with over a decade of follow-up	Fredrik Åberg	Received

SAT-496	Transient Elastography has limited efficacy for fibrosis assessment in End Stage Renal Disease patients on maintenance haemodialysis with suspected liver disease	Sunil Taneja	Received

THU-496	Assessment of fibrosis markers in a large cohort of chronic hepatitis B patients in Ethiopia	Hailemichael Desalegn	Received

FRI-496	Impact of sustained virologic response on liver fibrosis in recurrent hepatitis C after liver transplantation	Ezequiel Mauro	Received

FRI-497	Leaky gut does not affect the risk of infectious complications and survival in liver transplant recipients: comparison with cirrhotic patients and healthy individuals	Francesca Romana Ponziani	Received

SAT-497	Point shear wave elastography method for assessing liver stiffness in different etiologies of liver diseases – a prospective study	Tarek Saadi	Received

SAT-498	The novel point shear-wave elastography method ElastPQ is accurate for non-invasive evaluation of liver fibrosis and portal hypertension	Theresa Bucsics	Received

THU-498	Non-invasive multiparametric MRI (LiverMultiScanTM) effectively excludes NASH and liver fibrosis in at risk patients	Rajarshi Banerjee	Received

FRI-498	Personalized subcutaneous administration of hepatitis B surface antibodies without nucleos(t)ide analogues is highly effective and reduces cost for hepatitis B prophylaxis after liver transplantation	Rob Bielen	Received

THU-499	Characterisation of liver fat in the UK biobank cohort	Rajarshi Banerjee	Received

SAT-499	Impact of hepatic steatosis and controlled attenuation parameter (CAP) on accuracy of fibrosis staging using transient elastography	Thomas Karlas	Received

SAT-500	The effect of liver steatosis on non-invasive measurement of liver iron concentration by spin-density projection assisted R2-MRI (FerriScan)	Tim Guy St Pierre	Received

THU-500	Predicted prevalence and stratification of non-alcoholic fatty liver disease in a large population using non-invasive multiparametric MRI	Rajarshi Banerjee	Received

FRI-500	Acute rise in delta model for end-stage liver disease as a prognostic risk factor for post-transplant mortality: an analysis of a national registry	George Cholankeril	Received

THU-501	Novel mapping of fibrosis and hepatic inflammation in NASH patients with dual R2 MRI relaxometry	Claudia P Oliveira	Received

SAT-501	Clinical and prognostic associations of liver volume determined using computed tomography in patients with cirrhosis	Tiong Yeng Lim	Received

THU-502	Hepatic iron overload analysis bymagnetic resonance imaging in a non-alcoholic fatty liver disease population	Claudia P Oliveira	Received

SAT-502	Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein as a serum biomarker for disease severity in non-alcoholic fatty liver disease	Wah Kheong Chan	Received

FRI-503	Laparoscopic liver resection for hepatocellular carcinoma located in segments 7 or 8	Hanisah Guro	Received

THU-503	Serum immunoglobulin levels are related to histological severity of primary biliary cholangitis	Huan Wang	Received

SAT-503	Collagen formation and degradation biomarkers identify advanced fibrosis in NASH patients	Yi Luo	Received

SAT-504	A novel non-invasive Golgi protein 73 (GP73)-based model accurately diagnoses significant fibrosis in chronic liver disease	Zhujun Cao	Received

THU-504	Dynamic of liver stiffness values by means of transient elastography in patients with hepatitis C virus liver cirrhosis undergoing Interferon free treatment	Ioan Sporea	Received

FRI-504	Effects of liver transplantation on cardiac function in patients transplanted for NASH cirrhosis	Haripriya Maddur	Received

LBP-505	Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in Europe	Alison D. Marshall	Received

LBP-506	B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cholangitis: a randomised controlled trial (RITPBC)	Amardeep Khanna	Received

LBP-507	One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection	Andrew Vaillant	Received

LBP-508	Direct-acting antivirals for hepatitis C do not increase the risk of hepatocellular carcinoma recurrence after locoregional therapy or liver transplant waitlist dropout	Annsa C Huang	Received

LBP-510	Preventing decompensation of cirrhosis with clinically significant portal hypertension and without high-risk varices: a new indication for non-selective beta-blockers (NSBB)	Candid Villanueva*	Received

LBP-512	Circulatory microRNA-142 as potential biomarker of disease progression in paediatric cystic fibrosis-associated liver disease	Diego A. Calvopina	Received

LBP-513	A Notch receptor-selective Jagged1 mutation causes an Alagille syndrome phenotype in mice	Emma R Andersson	Received

LBP-514	Baseline neutrophil to lymphocyte ratio can identify favourable corticosteroid response in alcoholic hepatitis	Ewan Forrest	Received

LBP-515	Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH	George Kemble	Received

LBP-516	13C-Methacetin Breath Test accurately assesses clinically significant portal hypertension in patients with NASH cirrhosis	Guadalupe Garcia-Tsao	Received

LBP-521	Exploring the therapeutic potential of Glucagon/GLP-1 dual agonist ZP2929 in a mouse model of diet induced and biopsy-confirmed non-alcoholic steatohepatitis	Jolanta Skarbaliene	Received

LBP-522	Efficacy and safety of Glecaprevir/Pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 Study	Juergen Rockstroh	Received

LBP-523	A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysis	Laura Turco	Received

LBP-524	Severe periodontitis predicts higher cirrhosis mortality	Lea Ladegaard Grønkjær	Received

LBP-525	Epidemiology of hepatitis C infection in children and young people in the UK	Line Modin	Received

LBP-526	Safety, tolerability and treatment effectiveness of chronic hepatitis B patients with pradefovir: a phase 1b multiple ascending dose study	Liu Jingrui	Received

LBP-528	Incidence and prevalence of recorded non-alcoholic fatty liver disease in four large European primary care databases covering 21.9 million adults	Myriam Alexander	Received

LBP-529	Worldwide lack of early referral of patients with alcoholic liver disease: results of the global alcoholic liver disease survey (GLADIS)	Neil D Shah	Received

LBP-530	Degree of liver fibrosis regression predicted by transient elastography after cure of chronic hepatitis C with direct acting antivirals is overestimated but confirmed by liver biopsy	Paul Pockros	Received

LBP-531	The roles of glycogen synthase kinase-3 genes in liver functions	Prital Patel	Received

LBP-532	Potential viral triggers for pediatric and adult autoimmune hepatitis	Richard Taubert	Received

LBP-533	Prospective prevalence study of adult NAFLD/NASH utilizing multi-modality imaging compared with liver bopsy	Stephen A. Harrison	Received

LBP-536	Regulation of the mechanistic target of rapamycin complex 1 (mTORC1) - nuclear hormone receptor signaling by bile acids	Tarek Moustafa	Received

LBP-537	Impact of NASH, gender, fasting glucose and body mass index on the liver fibrosis transition rate (FTR) in metabolic liver disease (MLD)	Thierry Poynard	Received

LBP-538	Preclinical study of a combinatorial RNAi/vaccination therapy as a potential cure for chronic hepatitis B	Thomas Michler	Received

LBP-539	Autologous liver transplantation in end-stage hepatic alveolar echinoccossis with 51 patients´ experience--where do we stand?	Tuerhongjiang Tuxun	Received

LBP-540	Propranolol versus endoscopic variceal ligation in patients with cirrhosis and ascites- a randomised controlled trial	Virendra Singh	Received

LBP-543	iPLA2beta protects aged male mice from liver fibrosis and intestinal atrophy by modulating phospholipid and enterohepatic bile acid metabolism	Walee Chamulitrat	Received

LBP-544	High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4	Zobair M Younossi	Received

LBP-545	Handouts payed by paypal	Daniel Zaldumbide	Received

The International Liver Congress 2017

19-23 April 2017 Amsterdam

About us

This year, EASL offers you free printing, delivery and display of your poster at the The International Liver Congress™ 2017, in Amsterdam, the Netherlands.

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 18/04/2017 TO 18/04/2017

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum

DOI: 10.3252/pso.eu.ILC2017.2017



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions

Special Access

Commercial Web Access